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Introduction 
Human Immunodeficiency Virus (HIV) infection and Autoimmune 
Immunodeficiency Syndrome have had devastating effects upon the lives and 
deaths of many across the globe. 1 Within the United States, this epidemic remains 
an important public health issue. Although advances from medical research have 
done much to improve the mortality rates and quality of life among those infected, 
several studies and papers have highlighted an exclusion of U.S. minorities in 
these studies. 
This paper will address several topics regarding HIV I AIDS and U.S. blacks. First 
of all, the historical impact ofHIVIAIDS on the national and state (North 
Carolina) landscape for the general population will be explored through relevant 
scientific articles. Patterns of differential incidence, prevalence, mortality, and 
treatment according to race will also be discussed. These will be covered in the 
sections: 
• HIV I AIDS Morbidity & Mortality 
• HIVIAIDS and Race/Ethnicity 
Secondly, the inclusion of black U.S. citizens in medical research will be 
investigated. This will include a short discussion of the importance and 
implications for inclusion of African Americans in medical research. I will also 
provide an overview of the existing literatme regarding barriers and facilitators 
for African American participation in general and HIV I AIDS medical research. 
These will be covered in the section: 
• Black Americans and Medical Research 
The main scope of this paper, however, is to explore the predictors ofresearch 
participation among rural African Americans through a secondary data analysis. 
The former topics are meant to provide the backdrop on which this secondary data 
analysis will be outlined, discussed, and critiqued. Quantitative data from this 
small pilot sample will be analyzed, reported, and discussed as is common in the 
scientific literatme. Furthermore, there will be a clear research plan presented for 
a futme qualitative analysis meant to complement om quantitative analyses. 
These goals will be met in the following sections: 
• Objectives 
• Methods 
• Results 
• Discussion 
• Conclusion 
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HIV/AIDS Morbidity & Mortality 
HIV and AIDS surfaced in the U.S. during the late 1970s- early 1980s. The first 
five known cases of AIDS in the U.S. were discovered in June 1981.2 
Subsequently, the HIV/AIDS epidemic exploded and peaked during the 1980s 
and underwent stabilization and some reduction in incidence and mortality rates 
during the 1990s through the present. Efforts at disease surveillance have resulted 
in many measurements of incidence and prevalence among different risk groups, 
with relatively fewer measurements of overall incidence and prevalence among 
general populations. 3 This section will attempt to provide the best known 
estimates for the trends of overall incidence, prevalence, and mortality rates for 
HIV/AIDS in the United States. North Carolina HIV/AIDS epidemiology will 
also be briefly examined. 
HIV Incidence 
At present, the best evidence for incidence rates ofHIV/AIDS can be found in a 
systematic review by Vu, Steketee, Valleroy, and colleagues and in national 
estimates from the Centers for Disease Control and Prevention. 
In the afore-mentioned systematic review, the investigators reported HIV 
incidence rate estimates in Sexually Transmitted Disease (STD) Clinics as 2-
31100 ~-y during the late 1980s in Florida and< 11100 p-y in California in the 
1990s. Estimates from STD clinics are limited, however, in that they may 
represent populations participating in higher risk activities than the general 
population. Incidence rates may vary by region as well, which limits the ability to 
draw conclusions of a trend from the studies used in the above systematic review 
(Table 1). 
According to the CDC, an estimated 1.3-1.4 million persons were infected with 
HIV between 1981 and 2001.4 Peak HIV incidence is estimated to have been 
more than 150,000 people per year in the 1980s.5 Currently, it is estimated that 
40,000 new HIV infections have occurred annually since the early 1990s.6 
AIDS Incidence 
An estimated 816,149 AIDS cases have occurred between 1981 and 2001.6 
Incidence rates for AIDS cases peaked in 1993 and have since decreased 
dramatically (Figure 1).7 It is thought that the AIDS incidence declined 
substantially during the late 1990s due to the introduction of combination anti-
retroviral therapy. 
"From 1995 to 1998, the annual number of incident AIDS cases declined 
38% 
from 69,242 to 42,832, and deaths from AIDS declined 63%from 51,670 
to 
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18,823. The annual number of incident AIDS cases and deaths have 
remained stable since 1998, at approximately 40,000 and 16,000, 
respectively. "6 
More recently, a 2005 CDC report ofHIV/AIDS incidence in 33 states 
(representing 63% of all cases) reported 157,252 new HIV/AIDS cases from 
2001-2004.8 There was a statistically non-significant decrease in the incidence 
rate, 22.8 per 100,000 in 2001 to 20.7 per 100,000 in 2004. Caution must be used 
in interpreting their reported trend, however. First of all, the CDC launched their 
Advancing HIV Prevention (AHP) initiative in 2003. This may have resulted in 
increased testing, which would inflate the 2003-2004 incidence rates. Second of 
all, this report does not include data from California, among other states. The 
large population and unique demographics among those infected with HIV in 
California and other states could conceivably change their incidence estimates 
significantly. 
HIVIAIDS Prevalence 
A cross-sectional study examined HIV prevalence within four different counties 
in the Western U.S. for 1989-1990 9. HIV prevalence was reported as -2% in 
STD clinics in all counties except for San Francisco, for which it was reported at 
9.3%. This was a fair quality study limited by potential for measurement and 
selection bias. This study also lacks generalizability to national populations 
because of demographic characteristics specific to the Western U.S. (Table 2). 
Another study examining HIV prevalence rates during 1989-1990 focused on 
HIV-1 infection among those 15-49 years of age seeking care from primary health 
care providers in a nation-wide sample population (n=9,076). 10 They report an 
overall prevalence rate of2.3/1000 (95% CI 1.3-3.3). In addition, there was a 
prevalence rate of 1.0/1000 (95% CI 0.3-1.7) for previously undiagnosed HIV-1 
infection. Men were found to have an HIV -1 prevalence four times that of 
women, and non-rural practices to have a prevalence rate three times that of rural 
practices. This study was of good quality and presents results consistent with the 
current literature for that time period, as cited by the authors. This study can not 
be generalized to broad populations, however, because not everyone in general 
populations seeks care. Furthermore, their generalizability is limited by the age 
parameters of the sample and the racial composition, which is not nationally 
representative (Table 3). 
The CDC estimated HIV cases for 1986 and 1989 to be 750,000 and 1 million, 
respectively. Given the census population estimates fot those years, a rough 
estimation of prevalence for those years is 0.31% and 0.41% respectively. 11 • 12 
More recently, several investigators have attempted to measure HIV prevalence in 
primary care practices. Specifically, a cross-sectional study conducted in 2000 
measured prevalence of acute HIV infection among patients with symptoms of a 
viral illness who presented to an urgent care center at an urban teaching hospital 
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from March 30, 2000 to March 30, 2001. 13 They reported total HIV prevalence as 
2.2% (95% CI 0.9-3.5), acute HIV prevalence as 1.0% (95% CI 0.1-1.9), and 
chronic HIV prevalence as 1.2% (95% CI 0.2-2.2). This study was of good 
quality, had patient demographics similar to 72 other hospitals in the U.S., and 
reported prevalence estimates similar to those previously reported (Table 4). 
Another cross-sectional study conducted in 2000 measured prevalence of acute 
HIV infection in patients visiting physicians' offices, emergency departments, and 
hospital outpatient clinics. 14 All patients included in the study had symptoms 
consistent with primary HIV infection. They found those presenting with fever, 
rash, or pharyngitis to have HIV prevalence estimates of 0.66% (95% CI 0.53-
0.92), 0.56% (95% CI 0.35-0.94), and 0.13% (95% CI 0.10-0.19), respectively. 
The overall quality of this study is good, but it is not generalizable to those >54 
years of age, federal, veteran, and military outpatient facilities, and those wl 
undiagnosed chronic HIV infection (Table 5). 
The CDC estimates that 850,000--950,000 were living with HIV in 2002. Of 
these, approximately 25% were unaware of their serostatus6 The prevalence of 
AIDS has also risen dramatically since the late 1980's (Figure 2)(Figure 3). The 
HIV prevalence rate reported for 2004 by the CDC was 168.8 per 100,000 people 
(Figure 4). 
In short, HIV prevalence estimates vary depending on the population studied and 
the methods used. Despite this limitation, the afore-mentioned studies suggest a 
continuing HIV epidemic that is of profound public health importance within the 
U.S. Efforts aimed at slowing this epidemic have stabilized HIV incidence, but 
improved HIV I AIDS therapy are prolonging the lives of those infected. Thus, the 
number of those living with HIV I AIDS is increasing. 
HIVIAIDS Mortality 
From 1981-2001, the CDC estimates that 467,910 deaths occurred from 
HIVIAIDS.6 Mortality from HIVIAIDS rose steadily during the 1980's and 
peaked in 1995 at -55,000 per year (Figure 3)(Figure 5). From 1995 to 1998, the 
deaths from AIDS declined 63% from 51,670 to 18,823 annually. The annual 
number of deaths have remained stable since 1998, at approximately 16,000 per 
year. 15 A similar trend is observed when analyzing potential years of life lost 
from HIV (Figure 6). 
HIVIAIDS Epidemiology in North Carolina 
Similar to the national landscape, HIV and AIDS has become a serious problem in 
North Carolina as well. In 2004, N.C. reported 1,099 incident cases ofHIV, as 
well as an HIV prevalence rate, and AIDS prevalence rate higher than many other 
states in the U.S. (Figure 4)(Figure ?)(Figure 8). 
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N.C. HIV incidence was first seen to increase in 1990 after the institution of state-
required HIV infection reporting (Figure 9). Although HIV incidence in N.C. has 
decreased since its peak in the mid-1990's, incidence rates have recently appeared 
to increase again. This is thought to be from new surveillance methods that have 
added older prevalent cases to the system. 16 HIV and AIDS prevalence in North 
Carolina has also been reported as increasing as recent as 2004 (Figure 1 0). 
Lastly, there were 454 HIV/AIDS deaths reported in N.C. for 2003, which is 30 
less than in 2002. 16 It was ranked as the gth and 7'h leading causes of death for 
North Carolinians in the 15-24 and 25-44 age groups, respectively. 
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HIVIAIDS and Race/Ethnicity 
National Disparities in Epidemiology 
The early AIDS epidemic was characterized very strongly by race and 
transmission category. The CDC reports that in 1985, -60% and -65% of all new 
AIDS cases were among white Americans and men who have sex with men 
(MSM), respectively (Figure 11)(Figure 12). In addition to the large burden of 
AIDS among whites, other epidemiological measures of frequency indicated a 
growing inclusion of African Americans among the number infected. 
According to a fair quality systematic review exploring the extent of HIV I AIDS 
infections among black Americans, the estimated seroincidence for HIV from 
1985-1991 was 51.1 vs. 3.7 per 100,000 p-y for black and white Americans, 
respectively.17 They further report seroprevalence from 1988 - 1994 as 1.10% 
and 0.20% for black and white Americans ages 18-59, respectively. Thus, 
increasing numbers of African Americans were contracting HIV during the late 
1980s and early 90s. 
Since - 1994, black Americans have comprised a larger proportion of AIDS cases 
than white Americans (Figure 11 ). In 1998, black and white Americans were 
45.1% and 33.4% of all incident AIDS cases, respectively (Table 6). 1996 
unpublished CDC data reported by Smith and colleagues cites the HIV 
seroprevalence for black and white men age 16-21 as 0.22% and 0.04%, 
respectively. The 1996 HIV seroprevalence for black and white women age 16-
21 was reported as 0.35% and 0.07%, respectively. Similar patterns may be seen 
in a 1998 estimation ofHIV and AIDS incidence and prevalence (Table 7). 18 
More recent examinations of HIV I AIDS demographic distributions continue to 
show similar trends. 2003 HIV I AIDS diagnosis rates were estimated as 7 4 and 9 
per 100,000 for blacks and whites, respectively (Table 8). 2 At the end of 2003, 
48% of the HIV I AIDS cases were African Americans. The prevalence rate 
reported was 114 vs. 765 per 100,000 for white and black Americans, 
respectively. This data is limited by the inclusion of only the 32 states for which 
name-based reporting was available. The 2004 data, with the inclusion of New 
York, continued to show similar patterns (Table 9)(Figure 13)(Figure 14). 8 While 
the absence of data from other important states such as California certainly makes 
these reports less than ideal, they provide fair evidence for the continuing 
disproportionate burden ofHIV and AIDS among the black community. 
N.C. Disparities in Epidemiology 
Within North Carolina, there were 1,641 new HIV diagnoses in 2004.16 1,081 
(66%) of these were among blacks. The incidence rates ofHIV in N.C. were 
reported as 58.9 and 7.6 per 100,000 for blacks and whites, respectively. Overall, 
blacks made up 71% of the 17,960 individuals in N.C. living with HIV or AIDS 
in 2004. 
8 
National Disparities in HIV/AIDS Mortality 
In addition to African Americans acquiring HIV at an alarmingly high rate and 
comprising a higher proportion of the HIV and AIDS cases than white Americans, 
the HIV I AIDS epidemic has taken a large toll on black mortality rates. The 
HIVIAIDS estimated mortality rate for 1998 was 58.2 and 9.8 per 100,000 for 
black & white men, aged 25-44, respectively.17 The estimated mortality rate for 
women was 25.6 and 1.9 per 100,000 for blacks & whites, aged 25-44, 
respectively. 
In 2005, the HIVIAIDS Surveillance Report released data regarding survival time 
after AIDS diagnosis for 2000. 19 American Indians/Native Alaskans had the 
highest percentage of AIDS diagnoses surviving after 12, 24, and 36 months: 
92%, 89%, and 85%, respectively. Whites were reported as 91%, 87%, and 85%, 
respectively. 90%, 85%, and 81% of blacks survived for 12, 24, and 36 months, 
respectively. 
As recently as 2003, the CDC continued to report HIV mortality data for African 
Americans that was consistently higher than that of other races (Figure 15)(Figure 
16). Their report of mortality rates by race shows an approximate seven-fold 
difference between black Americans and white Americans. In addition, the 
estimated potential life years lost from HIV for blacks has and continues to be at 
least seven times greater than that for whites (Figure 17). HIV has been estimated 
to account for 11.2% of the racial disparity in potential life-years lost from all 
causes?0 
NC. Disparities in HIVIAIDS Mortality 
North Carolina surveillance data indicates large differences in deaths attributable 
to HIV and/or AIDS according to race. There were 453 such deaths in N.C. in 
2003. 16 74% of these were among blacks, while only 23% were in whites. This 
distribution was similar when stratified by sex. The crude .death rates for blacks 
and whites were 18.2 and 1.7 per 100,000, respectively. This large difference in 
crude death rates was also seen when stratified by sex. Reported death rates for 
males were significantly higher than those for females, however. 
Similar to national. HIV I AIDS reporting practices, survival data for AIDS 
diagnoses for the year 2001 have been released16 86.4%, 81.6%, and 81.0% of 
whites' AIDS cases were alive at 12, 24, and 36 months after their diagnosis, 
respectively. Blacks' AIDS cases survived at 89.7%, 85.0%, and 82.3% for 12, 
24, and 36 months, respectively. 
Thus, it appears that the proportion of black AIDS patients surviving over time is 
equivalent to, if not better than, that of white AIDS patients in N.C. These data 
are a notable improvement from the N.C. 1998 data, in which greater proportions 
of white AIDS patients were surviving than black AIDS patients. Thus, it appears 
that NC AIDS care is improving for black Americans. 
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The afore-mentioned pattern also shows 2001 N.C. black AIDS patients as 
surviving at equal or greater proportions than U.S. black AIDS patients in 2000 at 
24 and 36 months after diagnosis. This may represent better AIDS care in N.C. 
than in the U.S. as a whole. Alternatively, this may only be an improvement seen 
over time that would also be present in national 2001 data, were it available. 
The discrepancy between the mortality rates and survival proportions may be 
partially accounted for by the HIV attributable deaths not included in the 
proportion data. There may also be a significant number of African Americans 
with HIVIAIDS who are outside of the healthcare system. Thus, they may not be 
diagnosed until they are at or near death. In such cases, only approximately one 
third of such individuals would be captured in a three-year follow-up of survival 
when restricting date of diagnosis to the first year only. 
National Disparities in HIV/AIDS Care 
The 2002 Institute of Medicine Report on Health Care disparities acknowledges 
that U.S. minority populations are less likely to receive appropriate HIVIAIDS 
care than non-minority patients.21 It further reports that minority patients receive 
poorer quality HIV I AIDS care than non-minority patients, even when access to 
care is equivalent. A recent presentation by a well-known HIV I AIDS researcher 
similarly suggested that the specific racial disparities in HIV I AIDS care are 
currently recognized as problems obtaining HIV care and differential quality of 
HIV care.22 . 
Problems Obtaining HIVIAIDS Care 
Black Americans are disproportionately infected with HIV. Despite the gross 
imbalance ofHIV incidence and prevalence between racial groups, a nationally 
representative sample of all persons receiving HIV I AIDS care in 1999 found only 
33% of those receiving care to be Non-Hispanic blacks.Z3 Approximately 48% of 
HIV I AIDS cases are estimated to be black Americans.2 
In addition to the overall inadequate acquisition of HIV care by African 
Americans, there is also evidence that receipt of such care may be delayed 
differently according to race. Turner and colleagues report such an observation in 
a retrospective cohort study measuring time to receipt of first HIV medical care 
from the initial date of diagnosis in a national probability sample.Z4 They report 
African Americans as having 1.56 times the odds (95% CI 1.19-2.04) of having 
their HIV care delayed > 3 months compared to white Americans, after adjustment 
for several health care delivery, demographic, and socio-economic factors. Of all 
patients with delayed care for > 3 months, the median delay time was 1 year. 
Although this study is of overall good quality, it does feature inadequate 
measurement of patient trust and thus potential confounding from patient trust 
issues, as well as patient satisfaction and patient-provider communication. This 
data also represents trends recorded in 1996, which may not be relevant today. 
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The best evidence concerning HIV care disparities, however, is from a systematic 
review performed by Palacio and colleagues.25 Their analysis of28 studies 
spanning from 1984 to 1999 found 14 studies with a negative association, three 
with a positive association, and 12 with no association between race and HIV 
treatment. Seven studies also had mixed results across several measures of HIV 
treatment. Their critical analysis of these studies led to their conclusion that the 
overall evidence for racial disparities in HIV care is strong. This paper did not, 
however, document any attempt to acquire unpublished data to reduce publication 
bias. 
Differential Quality ofHIVIAIDS Care 
In 1999, Shapiro and colleagues reported on several quality of care measures in a 
retrospective, nationally representative sample of HIV I AIDS patients?6 At 
baseline, blacks had greater odds than whites of having <2 Outpatient visits in six 
months (OR= 1.49; 95% CI 1.06-2.09) and ~1 Emergency Department visit 
without associated hospitalization in six months (OR=l.72; 95% CI 1.23-2.13) 
after adjustment for CD4 count, age, sex, exposure, insurance, education, and 
geographic region. This adjusted model also showed blacks to have greater odds 
of not receiving ART (OR=2.16; 95% CI 1.54-3.05) and not receiving PCP 
prophylaxis (OR= 1.54; 95% CI 1.03-2.29) than whites. These differences were 
not statistically significant after a median 15 month follow-up. The investigators 
did show, however, differential lag times for dissemination of newer antiretroviral 
medications by race. Blacks waited a mean of 13.5 months while whites waited 
10.6 months (p<0.001 ). This raises the concern that these treatment disparities 
are not improving over time, but merely shifting to newer treatments. That is, as 
disadvantaged groups fully acquire yesterday's standard of care, the advantaged 
move on to the new standard of care. This study is of good quality and 
generalizable to the entire U.S., but uses sampling methods which may not 
include those with very poor access, the very healthy, and the less compliant. 
A later study of racial disparities in receipt ofHAART reports a similar trend for 
receipt ofHAART.27 Gebo and colleagues report African Americans as receiving 
HAART less often than white Americans (OR=0.84, 95% CI 0.73-0.96), even 
when adjusted for access to care, IV drug use, disease severity upon diagnosis, 
and other demographic variables. This suggests that mere availability of HIV 
care does not fully account for the treatment disparities reported. The quality of 
the HIV care may be sub-optimal. This retrospective cohort is of fair quality and 
limited by potential confounding from socioeconomic status and possible medical 
or patient reasons for not receiving HAART. In addition, these results do not 
generalize nationally, nor to all HIV care sites, because the sample is not 
nationally representative and the participating sites were all highly experienced in 
HIV I AIDS treatment. 
In 2003, Ghaui and Anderson reRorted on receipt ofHAART within the HIV 
Insight™ (APACHE) database.2 This database is comprised of U.S. HIV 
patients receiving outpatient care in various non-disclosed locations. African 
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Americans were less likely to receive HAART as their first ART than whites 
(OR=0.59; 95% CI 0.50-0.71) when adjusted for age and year of starting ART. 
Although this fair quality evidence supports previous findings, the limited 
information on demographics and sampling design limits external validity and 
introduces potential for selection bias. In addition, various regional 
characteristics, patient characteristics, physician characteristics, and disease status 
may all confound the relationship between race and receipt of HAART as their 
first ART. 
Possible Explanations for the HIV Care Disparity 
Several studies have explored possible explanations for HIV treatment disparities. 
Inadequate HIV testing rates has been proposed as a potential barrier. Failure to 
diagnose HIV seropositive individuals precludes receipt of proper care. A greater 
proportion of African Americans, however, receive HIV testing than white 
Americans.29 Although notable, an estimated 25% of prevalent HIV cases in 
2002 were not aware of their serostatus. 6 It is possible that blacks are 
disproportionately represented among the 25% who are unaware. In such a case, 
the higher testing rates among blacks, which are far from I 00%, may not be 
enough to identify and lead equitable numbers of infected blacks to seek proper 
medical care.Z9 In addition, the unaware HIV positive blacks may be unmeasured 
or unsampled in studies of incidence/prevalence, but represented in the data 
currently supporting disparities in access to HIV care. In short, the 25% whom 
are unaware of having HIV may be accounting for the difference in treatment 
rates. 
In addition, fear of a positive HIV test result may deter individuals from seeking 
HIV testing. Ebrahim et al. hypothesizes that knowledge of HIV treatments may 
decrease such fear.Z9 Their survey showed blacks to have lower odds of knowing 
that HIV/AIDS treatment exists than whites (OR= 0.58, 95% CI 0.51-0.66). 
Thus, a difference in HIV knowledge between racial groups may play a role in the 
disparity in HIV treatment. 
In the fore mentioned retrospective cohort from Shapiro and colleagues, blacks 
were found to have statistically significant poorer quality of care than whites in 
four of six measures. 26 The authors noted, however, that the addition of insurance 
to their statistical models attenuated the association between race and the six 
quality measures considerably. Thus, possession and type of insurance may play 
a significant role in the racial disparity in HIV treatment. 
Provider mediated delay of antiretroviral treatment because of concerns about 
patient adherence has also been explored. A good quality prospective cohort 
study found that blacks received protease inhibitors later than whites, regardless 
of providers' "prescribing attitudes. "3° Furthermore, providers have been shown 
to inadequately discern which patients will be adherent to antiretroviral therapy_3 1• 
33 Given the recent evidence of no association between being African American 
and becoming less adherent for all who were initially 100% adherent (p=0.26), it 
is unethical for providers to withhold treatment based on race.34 Further 
investigation for predictors of becoming less adherent over time in blacks may 
provide more insight into this issue. 
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Blacks have also been shown to have unequal access to providers with HIV-
related expertise. Heslin and colleagues report blacks as having lower odds of 
having an infectious disease specialist for their HIV care than whites (OR=0.60, 
95% CI 0.37-0.95), but no difference in provider HIV patient volume (OR=0.93, 
95% CI 0.77-1.11).35 While offair quality, this study does not account for 
physician knowledge. In addition, the specialty and HIV patient volume, which 
were modeled separately but are conceivable related, were not covariates in each 
others' model. The results remain important, however, because specialty training 
and experience (HIV case load and years in medical practice) are associated with 
choosing guideline-concordant treatment regimens 3 
Lastly, racial concordance between patient and provider has been explored for an 
association with time to receipt of protease inhibitors. Using a nationally 
representative sample, King and colleagues report that white patients with white 
providers receive protease inhibitors sooner (median 278 days) than black patients 
with black providers (median 419 days; p<0.01) and black patients with white 
providers (median 443 days; p<0.001). Furthermore, after adjustment for patient 
and provider characteristics and provider attitudes, blacks with same race 
providers received protease inhibitors sooner than whites with same race 
providers (p<0.05) while blacks with white providers received protease inhibitors 
later than whites with same race providers (p<0.05). Limitations for this fair 
quality study include non-differential measurement biases such as inadequate 
measurement of trust and recall bias, selection bias through exclusion of 9% of 
sample who could not identify an HIV care provider, and potential confounders 
such as regional standard of care, patient participation with provider, patient-
physician communication, and several domains of trust that were not measured. 
L 
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Black Americans and Medical Research 
Black Americans Underrepresented in HIV Research 
Black Americans are disproportionately infected with HIV and AIDS. Recent 
data shows blacks to comprise a large portion of incident and prevalent HIV and 
AIDS cases (Figure II )(Figure 13)(Figure 14). 2· 8 In addition, affected blacks 
have mortality rates and estimated potential life-years lost~ I 0 and ~6 times 
greater than whites, respectively (Figure 15)(Figure 17). Even treatment for HIV 
and AIDS is utilized differentially between races in the U.S 21 
Despite these staggering inequalities, much of the HIV targeted research does not 
include adequate representation from those who are affected most by this illness: 
black Americans.37 In fact, this is true of blacks' emollment in research trials for 
several diseases, including diabetes, cardiovascular disease, HIV I AIDS, and 
cancer, among others. 38• 39 The following sections will concentrate on: 
I. A brief overview of blacks' nonparticipation in all research trials. 
2. Barriers for blacks' nonparticipation in all research trials. 
3. Barriers for HIV/AIDS trials, specifically. 
Background: Nonparticipation of black Americans in Clinical Research 
In 1972, one of the most well-known examples of unethical research carne to 
light: the Tuskegee Syphilis Study.40 The United States Public Health Service 
observed the natural history of untreated syphilis in 400 black men in Macon 
County, AL. These men were told they were receiving treatment when in fact 
they were not. This continued until 1972 despite the availability of bismuth and 
arsenic, and the later discovery of penicillin, as effective treatment for syphilis. 
More than I 00 men participating in this study succumbed to syphilis and its 
complications. 
This widely publicized breach of research ethics led to considerable changes, such 
as the creation of the National Commission for the Protection of Human Subjects 
of Biomedical and Behavioral Research and the National Research Act. 
Subsequent changes involved stronger protection of vulnerable populations and 
ensuring that risks arid benefits associated with clinical research are minimized 
and maximized, respectively. Institutional Review Boards have served as one 
means to that end. 
After these changes, inclusion of minorities in clinical research became unusual.40 
This transition to an opposite extreme has several fallacies. First of all, 
disproportionate research inclusion violates the bioethical principle of justice. In 
short, all risks and benefits of clinical trials should be evenly distributed among 
individuals, communities, and society.41 Presently, whites undertake 
disproportionately higher risks and receive disproportionately more benefit from 
medical research, as compared to blacks. 
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In addition, research subjects must be representative of their general population to 
ensure generalizability to society. When representative samples are not used, 
potential differences in efficacy and/or effectiveness of interventions by omitted 
demographic groups may go undiscovered. 39• 42 This results in treatments 
developed for only certain segments of our population. 
Increased awareness of race and sex-based omissions in research inclusion led to 
the NIH Revitalization Act of 1993.40 This legislation mandated that minorities 
and women all be included in clinical research unless there are strong reasons for 
their exclusion. The goals of minority inclusion in research have since been 
further clarified and summarized by one researcher as: 
I. Generating hypotheses about possible differences by race. 
2. Testing hypotheses of differences by race. 
3. Ensuring fair and unbiased sharing of the risks and benefits of research 
. . . 43 participatiOn. 
Although these ideals have been embraced by funding agencies such as the NIH, 
investigators have not uniformly changed reporting practices for clinical research. 
In a good quality systematic review, Corbie-Smith and colleagues examined 
reporting practices in three widely known and read general medicine journals, 
Annals of Internal Medicine, JAMA, and New England Journal of Medicine, for 
four diseases with established disparities based on race. Of 253 articles from 
1989 to 2000, 98% of these did not focus on a single race and 41% of these did 
not report the race/ethnicity of their study participants. In addition, when 
considering year of publication, year that recruitment started, the disease studied, 
and funding source, only the disease being studied was significantly associated 
with race reporting (OR=3.7; 95% CI 2.0-6.8). Although this study has good 
internal validity, some assessment of confounding by specific journal, sample size 
of study, or race of investigators or editors, if feasible, would have added further 
insight to their results. Furthermore, their generalizability is limited by inclusion 
of only three journals and only four diseases. These journals do, however, reach 
very wide audiences. 
Corbie-Smith's finding that year of publication was not associated with reporting 
race is especially disturbing given that previously mentioned ethical guidelines 
and well known reporting guidelines, such as the CONSORT statement, were 
published in the mid-90's. In 2001, the NIH revised their guidelines on minority 
research inclusion to stress subgroup analyses when prior evidence suggest 
differences by race or ethnicity.44 
Barriers for Participation in Clinical Research 
Investigations regarding nonparticipation in clinical research are well represented 
in the literature. Of particular interest is a fairly recent systematic review of 
patient and physician barriers to participation in randomized trials (Table I 0).45 
From an extensive literature search ofMedline, Embase, and CINAHL from 1986 
to 1996, they identified 78 eligible papers. Potential barriers to patients were 
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identified as patient concerns such as additional demands on patient, patient 
preferences for a particular treatment, worry about uncertainty of treatment or 
trials, and patient concerns about information and consent. Physician concerns 
hindering patient participation were protocol causing problems with recruitment, 
clinician concerns about information provision to patients, and clinician 
influencing patient decision not to join. 
This paper is notable within this discussion, however, not for what it reports, but 
for what it does not report. There is no mention, stratification, or other such 
analysis by race within this paper. Of the 78 eligible papers summarized, only 
three can be identified as targeting ethnic minorities from their titles or study 
descriptions. Given the past severe exclusion of blacks in research, it is unlikely 
that the other 7 5 studies account for a proportion of blacks proportionate to those 
who are targeted for research participation. 
Barriers for black Americans' Participation in Clinical Research 
Recruitment of minorities for clinical research has proven to be difficult for 
investigators.46 Efforts successful for enlisting white participants may not work 
as well for blacks.47 This has motivated several researchers to investigate the 
barriers, facilitators, and solutions to research participation among African 
Americans. 37• 42• 46• 48-51 The remainder of this discussion will focus on the 
reported barriers in such studies. 
A relatively older qualitative study used telephone interviews in 1993 to generate 
hypotheses about why African Americans do not participate in clinical research in 
Buffalo, NY. Eight African Americans reported "fear", "lack of information," 
"mistrust of being treated like guinea pigs," and "mistrust of white people. "42 
Another qualitative study utilized focus groups in 1997 to generate hypotheses 
about barriers clinical research among blacks in Atlanta, GA.48 After reaching 
saturation, Corbie-Smith and colleagues report five focus groups as indicating 
mistrust, inconvenience, too much risk, fear of injections and needles, concerns 
about physicians being fully honest about risks and procedures, no need because 
of current good health, and non-sharing of final research benefits with the black 
community as being deterrents to their participation in clinical research. The 
groups also identified the Tuskegee study as justification for their mistrust 
regarding researcher dishonesty and non-beneficence. The internal validity for 
this study was strong. These results are also most generalizable to women, the 
poor, and the uninsured. 
A third qualitative study investigating perceptions of clinical research recruited 60 
African Americans from Los Angeles, Chicago, Washington, D.C., and Atlanta 
for participation in seven focus groups (Table ll ).46 Barriers reported for these 
groups were distrust of white researchers, privacy, full awareness of treatment 
allocation, and the high risk. Some groups did, however, distinguish between 
non-invasive research (ex. surveys, focus groups, etc.), which was more 
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acceptable, versus research involving invasive interventions (ex. medications, 
surgeries, etc.). Although the researchers do not report reaching saturation, their 
methods suggest strong internal validity and improved external validity in 
comparison to the previously mentioned qualitative studies. 
A recent analysis of four focus groups composed of staff, students, and faculty 
from the University of Minnesota Twin Cities campus investigated factors that 
impede research participation among minorities. 5° Comprised of -56% African 
Americans, these groups most often identified limited knowledge about health 
studies, limited community involvement in the design of studies, use of invasive 
procedures, and mistrust of researchers as potential impediments. The Tuskegee 
study was also brought up by five of the 10 African Americans as a potential 
barrier. This study is limited by poor explanations of their selection process, and 
measurement and analysis techniques. The participants were also considerably 
homogenous regarding higher education, female sex, highly health conscious, and 
geographic region. This study represents fair quality internal and external 
validity. 
Regarding quantitative research, Shavers and colleagues examined whether 
differences of prevalence of socio-cultural beliefs accounted for the difference in 
willingness of African Americans to participate in research (Table 12).51 With 
multivariate modeling, knowledge of the Tuskegee Study and changes in trust 
resulting from knowledge of the Tuskegee study predicted African American 
willingness to participate in clinical research. In contrast, educational level and 
beliefs regarding the racial sharing of medical research risks predicted the 
willingness of white Americans to participate in clinical research. Lastly, the 
authors concluded that "the role of Tuskegee appears to lie with its contribution to 
the overall distrust of medical research among African Americans. "51 This last 
observation mirrors that made by Corbie-Smith and colleagues in their fore-
mentioned qualitative analysis.48 
Although Shavers and colleagues present thought provoking results, their internal 
validity is weakened by reporting inconsistencies within this publication as well 
as with their previous publication reporting only results for African Americans, 
questionable statistical methodology, differential non-coverage bias, only a 36% 
response rate, and non-differential measurement bias from two different survey 
techniques. 51' 52 
In 2002, Corbie-Smith and colleagues tested a previously generated hypothesis 
regarding the association between race and trust regarding clinical research (Table 
13)53 After controlling for education, employment, and geographic region, 
blacks race was significantly associated with having more distrust (OR=4.7; 95% 
CI 2.9-7.7). Mild selection bias may have occurred from requiring the possession 
of a telephone. Thus, those at the lowest and highest extremes of SES may have 
been excluded through not having a phone and being too busy, respectively. 
Although sex was significantly related to the outcome, distrust (p=0.02), it was 
not included in the model because there was not a statistically significant 
association with the exposure, race (p=O.l4). This author questions the 
appropriateness of that decision and considers sex a potential confounder. 
Overall, however, this study exhibits good internal validity and results likely 
generalizable to the entire U.S. population. 
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Barriers for black Americans' Participation in HIVIAIDS Clinical Research 
Consistent with the increase in research regarding barriers to minority 
participation in all clinical research, there have also been several such trials 
dealing with HIV/AIDS trials specifically. One such cross-sectional survey 
administered between 1993 and 1994 measured participation rates by sex and 
explored differences in reasons for non-participation by various demographics 
(Table 14).54 Whites were found to participate at higher rates than persons of 
color (OR=2.14; 95% CI 1.12-4.08) after adjusted for disease severity, age, 
education, and clinic type. For non-participators, the most common reasons cited 
were not informed about trials (28%), not interested or did not want to (28%), fear 
of experimentation (20%), and not eligible (14%). When stratified by race, 
Persons of color were significantly more likely to report no interest (31.9% vs. 
16.4%, p<0.05) and less likely to report not eligible (1 0.4% vs. 22.4%, p<0.05). 
This study is limited to fair internal validity from potential confounding and 
measurement bias from racial concordance of study interviewer, confounding 
from patient learning of clinical trials outside the clinic, and possible selection 
bias from convenience sample. This study is also only generalizable to patients in 
care, the poor, symptomatic, and urban. 
A later study by Sengupta and colleagues test institutional distrust as the primary 
factor affecting research participation using a multidimensional construct.37 They 
found distrust to be the strongest inverse predictor of willingness to participate in 
clinical research among 301 African Americans in Durham, NC. Other factors 
significantly associated with participation were altruism, facilitators/barriers, 
religiosity, and economic group membership. Of importance to this discussion, 
over half of the facilitators/barriers construct was accounted for by issues of 
transportation and number of visits to the study site. Although this study appears 
to be of good internal validity, this author needs further instruction to determine 
its true quality. In addition, the results may not be widely generalizable. 
The best evidence for barriers to HIV trial participation, however, is likely a 
recent systematic review by Mills and colleagues (Table 15).55 Its strong internal 
validity involves extensive search techniques, concrete selection and grading 
criteria, and reliable analysis techniques. Furthermore, two of the five qualitative 
studies and six of the nine quantitative studies analyzed have equitable or near-
equitable enrollment of black and white Americans, lending great strength to the 
external validity. 
Three of the five qualitative studies identified themes regarding safety, pragmatic 
obstacles, and discrimination/social issues. Four of these studies identified fear or 
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mistrust as a barrier, while all five identified concerns about research design as a 
barrier. For the barriers identified among the quantitative data: 
• Three studies identified discrimination as a barrier to research 
participation. 
• Five studies identified safety as a barrier. 
• Six studies identified concerns about research design as a barrier. 
• Eight studies identified fear or mistrust as a barrier. 
• Eight studies identified pragmatic issues as a barrier. 
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Objectives 
Although there is evidence available regarding barriers to research participation 
among minorities, and black Americans in particular, this area of research is by 
no means saturated or all inclusive. In particular, studies investigating minority 
participation in HIV and AIDS clinical research generally involve urban 
populations. As seen in North Carolina and others states, however, an increasing 
proportion ofHIV and AIDS cases live in rural areas. Inclusion of rural 
minorities in HIV/AIDS research may in fact involve obstacles unique to their 
environment. In short, the barriers to HIV I AIDS research participation among 
rural African Americans may be different than those in urban or suburban African 
Americans. The relative importance of certain barriers may also vary for this 
population as well. 
In this investigation, we will use qualitative and quantitative methods to generate 
as well as test hypotheses about barriers to participation in clinical research 
among rural African Americans in North Carolina. My objectives are: 
• To investigate which characteristics are associated with past research 
participation among our sample using quantitative methods. 
• To outline the methods for a future qualitative analysis of the respondents' 
interviews. 
• To compare the quantitative results with the existing scientific literature. 
• To draw conclusions regarding possible solutions to minority non-
participation in medical research. 
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Methods 
Recruitment 
Participants were recruited from three NC sites: the Robeson County Health 
Department (RCHD), the Rocky Mount Opportunities Industrialization Center 
(OIC), and at the UNC General Clinical Research Center (GCRC) in Chapel Hill. 
Onsite staff identified potentially eligible participants for inclusion into this 
sample. Eligible individuals were ethnic minorities living with HIV or AIDS who 
were 18 years of age or older. 69 individuals with HIV I AIDS were asked to 
participate, and 4 7 completed interviews. 
Data Collection 
Participants were interviewed via a semi-structured interview guide, consisting of 
open-and close-ended questions. All interviews were audio recorded, transcribed 
into an electronic text document, and reviewed twice for accuracy and 
completeness. 
Questionnaire Design 
Three questionnaires were developed and color coded according to answers from 
several preliminary questions (see Appendix I & II). These questions separated 
respondents into those who have previously enrolled in a research study, those 
who have been asked to participate but have never enrolled, and those who have 
never been asked. Each questionnaire consisted of open- and close-ended 
questions. This format allows exploration of patients' underlying motivations, 
explanations, or feelings about their responses. Each questionnaire queried 
participants about their experience related to research participation. Data were 
also collected about HIV I AIDS experiences, and non-identifiable demographic 
characteristics, which will enable some assessment of possible confounders. 
A previously validated scal.e was adapted to assess participant trust in HIV 
researchers 56. The scale consists of 11 items, has a Cronbach alpha of 0.89, and 
explores four of the five previously conceptualized domains of trust: fidelity, 
competence, honesty, and global trust. The question regarding the fifth domain, 
confidentiality, did not correlate well with the overall scale (0.37) and was 
therefore deleted from the final construct. The absence of this last domain is 
significant, given the vulnerability of this study population and the focus of our 
study question. The inclusion of open-ended prompts within the 
questionnaire/interview, however, is adequate for recording any confidentiality 
concerns related to research participation. 
Questions assessing participant motivation for research participation were adapted 
from two previously published studies examining this topic in psychiatric and 
cancer patients, respectively 5 7· 58 
Quantitative Analysis 
All quantitative data was entered into electronic documents by two persons for 
verification. Entry ranges and checks were used to minimize errors. 
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All variables were examined for normal distribution using means for continuous 
variables, medians for categorical variables, and histograms when appropriate. 
Bivariate analysis was performed using Pearson's Chi-square test or Fisher's 
Exact test for comparisons of categorical variables. Two-sample t-tests or Wilcox 
Rank Sum were used for comparisons of continuous and categorical variables. 
Non-rural housing, race, receipt of public assistance, armual income, educational 
level, and employment status are the socio-demographic characteristics 
hypothesized to be associated with past trial participation. Being asked to 
participate in a clinical trial, transportation, trust in medical researchers, current 
likelihood of trial participation, expected medical benefit, and not having a better 
option for obtaining HIV -related care are also hypothesized to be related to past 
research participation. 
Qualitative Analysis Plan 
Using multiple teams of two members, the questionnaires were reviewed to 
develop coding categories. All responses were categorized according to themes, 
which were named, described, and recorded. This process continued until no new 
categories arose and reviewers reached consensus on categorization of responses. 
Codes and sub-codes were subsequently developed for each category, organized, 
and applied to the comments within the first twenty six interviews. Coded 
interviews were then reviewed by another reader to ensure consistency. 
For this future portion of my analysis, I will review the previously developed 
codebook and code the remaining questionnaires, applying labels to relevant 
themes within the text. This process will be repeated independent! y by another 
reader and reviewed with me to ensure consistency. Themes relevant to this 
analysis will then be tabulated and reviewed in detail for qualitative analysis. 
Results 
Univariate Analyses 
Demographics 
Forty seven individuals were verbally consented for completion ofthis study. 
They were recruited from three study sites at similar distributions. 74.5% of 
respondents were Black and 87.2% lived in non-urban areas. Males comprised 
55.3% of the sample and mean age was 42.4. Respondents reported having 
completed less than 12 years, 12 years, and more than 12 years of education at 
25.5%, 36.2%, and 38.3%, respectively (Table I). 
Annual income of less than $5000, $5000 - $20,000, and greater than $20,000 
were reported by 34.0%, 42.6%, and 23.4%, respectively. 21.3% reported 
working full time while 57.5% were unable to work and received public 
assistance. Health insurance status was also reported, with 25.5% having none 
(Table I). 
HIV/AIDS Experiences 
The median days since HIV/AIDS diagnosis was 1825 for this sample. 91.5% 
were currently on HIV medications. 95.7% thought that HIV meds were 
"definitely worth taking" (Table I). 
Clinical Research Experiences 
Among the 49 respondents, 51.1% had been previously asked to participate in a 
clinical trial and 40.4% had been previously emolled in a clinical trial. 
Clinical Research Perspectives 
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87.2% of our sample reported their current likelihood of trial participation as 
somewhat or very likely. Transportation was a major barrier for participation in 
clinical trials among 34.0%. On the trust in clinical research scale, ranging from 
11 to 55, the mean score was 42.9. Wanting to help future HIV patients and 
wanting to be a part of research were reasons for participation among 89.1% and 
56.5%, respectively. 37.0% reported persuasion from family. Finally, 84.8% and 
43.5% indicated medical benefit for self and no better option for obtaining HIV 
medications as major reasons, respectively (Table I). 
Bivariate Analyses 
Demographics 
Location of the participants' recruitment site was associated with past 
participation in a clinical trial (p<0.001). Those from the GeRe participated at 
100%, compared to 17.7% and 12.5% from the ore and the ReHD, respectively. 
The difference in past participation between the GeRe and the ore (p<O.OO 1) 
and between the GeRe and the ReHD (p<0.001) were both significant. The 
difference between the ore and the. ReHD was not statistically significant. Sex, 
age, residential description, and race did not have a statistically significant 
relationship with the outcome (Table II). 
Socio-economic Status (SES) 
23 
Annual income, educational level, and insurance type were all associated with 
past participation in clinical trials. Those with higher incomes had a greater 
history of past trial participation than those with lower incomes (p=0.025). When 
examined by pairs, only the difference between those with less than 12 years of 
education and those with more than 12 years of education was significant 
(p=O.Ol5) (Table II). 
Respondents with higher educational levels also participated more than those with 
lower educational levels (p<O.OO 1 ). There was no significant difference between 
those with less than 12 years of education and those with 12 years of education 
(0.370). The difference between those with less than 12 and more than 12 years 
(p<0.001), as well as between those with 12 vs. more than 12 years (p=0.002), 
were both significant. 
The association between past participation and insurance type was statistically 
significant (p=0.028). When examining differences by pairs, only that between 
private insurance and Medicaid was significant (p=0.008). 
Receipt of public assistance, full time employment, and inability to work were 
not associated with past participation. 
HIV I AIDS Experiences 
Time since HIV I AIDS diagnosis was significantly associated with past trial 
participation. Those who have not participated in clinical trials have known of 
their diagnosis more than three times as long as those who have participated 
(p=0.006). In addition, predictions based on this association reveal past trial 
participation to decrease as the length of diagnosis increases (p=O.Ol5). Currently 
being on HIV medications and perceptions of the medications' worth were not 
associated with past trial participation (Table II). 
Clinical Research Experiences 
Respondents who have been asked to participate in a clinical trial have a greater 
history of past participation than those who have never been asked (p<O.OO 1 ). 
Clinical Research Perspectives 
Available transportation and trust in clinical researchers were not associated with 
past participation. Current likelihood of participating in clinical research was also 
not associated with past participation (Table II). 
Among possible reasons for participating in clinical trials, family persuasion 
(p=0.013) and having no better option for obtaining HIV therapy (p=O.Ol 0) were 
associated with past trial participation. Wanting to help future HIV patients, 
possibility of medical benefit, and wanting to be a part of research were not 
significantly associated with past trial participation. 
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Table I. Characteristics 
Characteristics 
N=47 
Sex 
Male 
Female 
Location 
GCRC 
OIC 
RCHD 
Residential Description 
Non urban 
Urban 
Race 
Non-Black 
Black 
Receiving Public Assistance 
Yes 
No 
Annual Income 
<$5,000 
$5,000- $20,000 
> 
Education Completed 
< 12 years 
12 years 
> 12 
Insurance 
Private 
Medicare 
Medicaid 
Other 
None 
Employment 
Full Time Employed 
Yes 
No 
Unable to Work 
Yes 
No 
14 (29.8%) 
17 (36.2%) 
16 
27 (57.5%) 
20 
16 (34.0%) 
20 (42.6%) 
ll 
12 (25.5%) 
17 (36.2%) 
18 
8 (17.0%) 
8 (17.0%) 
18 (38.3%) 
l (2.1%) 
12 
10 (21.3%) 
37 (78.7%) 
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Median Range 
Previously Asked to be in Clinical 
Trial 
Yes 
No 
Previously Enrolled in a Clinical 
Trial 
Yes 
No 
Transportation 
"Big Problem" 
"Somewhat of a problem 
or not a 
Likelihood of Trial Participation 
Somewhat or Very Likely 
Somewhat or 
Major Reasons for Participating 
in Trials (n=46) 
Wanting to help future HIV 
patients 
Possibility of medical benefit for 
self 
Family Persuasion to Participate 
Wanting to be a part of research 
No better option for receiving 
HIV 
Tx 
24 (51.1 %) 
23 (48.9%) 
19 (40.4%) 
28 (59.6%) 
16 (34.0%) 
31 (66.0%) 
41 (89.1 %) 
39 (84.8%) 
17 (37.0%) 
26 (56.5%) 
20 (43.5%) 
GCRC- UNC General Clinical Research Center 
OIC- Rocky Mount Opportunities Industrialization ~enter 
RCHD- _Robeson ~ounty Health Department 
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Table II. Bivariate Associations Between Past Trial Participation 
and * 
Previously Enrolled in p 
a Clinical Trial value 
Total 
N=47 
~~~==~n=19 
Sex 
Male 
Female 
Mean Age (S.D.) 
Predictions for Age 
20 
30 
40 
50 
60 
Location 
GCRC 
OIC 
RCHD 
Residential Description 
Non-urban 
Urban 
Race 
non-Black 
Black 
Receiving Public 
Assistance 
Yes 
No 
Annual Income 
<$5,000 
$5,000 - <$20,000 
Employment 
Full Time Employedt 
Yes 
No 
Unable to Work 
Yes 
55.1 
47.8 
40.6 
33.8 
27.6 
100.0% 
17.7% 
12.5% 
15 (36.6%) 
4 
8 (29.6%) 
11 
3 (18.8%) 
8 (40.0%) 
8 
7 (70.0%) 
12 (32.4%) 
0.373 26 (55.3%) 
21 
0.391 
<0.001 14 (29.8%) 
17 (36.2%) 
16 
0.204 41 (87.2%) 
6 
0.737 
0.080 27 (57.5%) 
20 
0.025 16 (34.0%) 
20 (42.6%) 
11 
0.066 10 (21.3%) 
37 (78.7%) 
0.080 27 
<12 years 
12 years 
>12 
Private 
Medicare 
Medicaid 
Other 
None 
Median Days (95% CI) 
Predictions for Years 
0 years 
5 years 
10 years 
15 years 
20 
Currently on 
Medications t 
Yes 
No 
HIV Meds are: 
Definitely Worth 
Taking 
Not Definitely Worth 
Previously Asked to be in 
Clinical Trial 
Yes 
No 
Clinical Research 
Mean Trust Score 
(S.D.) 
Predictions for Trust Score 
II 
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1 (8.3%) 
4 (23.5%) 
14 
6 (75.0%) 
4 (50.0%) 
3 (16.7%) 
1 (100%) 
912.5 
(429.0-2460.9) 
67.7 
40.8 
18.4 
6.9 
2.4 
18 (41.9%) 
1 
19 (42.2%) 
0 (0.0%) 
79.2% 
11.3 
18.4 
28.6 
28 
<0.001 12 (25.5%) 
17 (36.2%) 
18 
0.028 8 (17.0%) 
8 (17.0%) 
18 (38.3%) 
1 (2.1 %) 
12 
0.006 1825 
(1095.0-
3089.4) 
O.oi5 
0.638 43 (91.5%) 
0.508 45 (95.7%) 
2 (4.3%) 
<0.001 
0.330 
29 
44 41.6 
55 55.9 
Transportation 
"Big Problem" 5 (31.3%) 0.357 16 (34.0%) 
"Somewhat or No 14 (45.2%) 31 (66.0%) 
Problem" 
Current Likelihood of Trial 
Participation t 
Somewhat or Very 19 (46.3%) 0.068 41 (87.2%) 
Likely 
Somewhat or Very 0 (0.0%) 6 (12.8%) 
Unlikely 
Major Reason for 
Participating in Trial? 
Wantin~ to help future HIV 
patients 
Yes 18 (43.9%) 0.387 41 (89.1 %) 
No 1 (20.0%) 5 (10.9%) 
Possibility of medical benefit 
for selft 
Yes 16 (41.0%) 1.000 39 (84.8%) 
No 3 (42.9%) 7 (15.2%) 
Family Persuasion to 
Participate 
Yes 3 (17.7%) 0.013 17 (37.0%) 
No 16 (55.2%) 29 (63.0%) 
Wanting to be a part of 
Research 12 (46.2%) 0.446 26 (56.5%) 
Yes 7 (35.0%) 20 (43.5%) 
No 
No better option for receiving 
HIVTx 4 (20.0%) 0.010 20 (43.5%) 
Yes 15 (57.7%) 26 (52.5%) 
No 
*All sigmficance tests for comparisons based on Pearson's Chi Square for categoncal 
variables and 2-sample t-test for continuous variables unless otherwise specified. 
tSignificance test based upon Fisher's Exact Test. 
tSignificance test based upon Wilcox Rank Sum. 
Abbreviations: 
GCRC - UNC General ~linical Research ~enter 
OIC- Rocky Mount Opportunities Industrialization ~enter 
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RCHD -_Robeson Qonnty .!:.!ealth Department 
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Discussion 
Interpretation of Results 
This study was meant to measure past clinical research participation among 
minority populations in North Carolina. North Carolina represents a novel setting 
for such research because of its large rural population and geographic proximity 
to historical injustices acted out according to race. The rural landscape is thought 
to impose unique barriers to healthcare acquisition and clinical research 
utilization. The Southern U.S. legacy of slavery, Jim Crow practices, and 
segregation may also exacerbate these issues among ethnic groups such as 
African Americans, Hispanics, and Native Americans. 
Univariate Findings 
The sample utilized for this study is thought to provide reasonable representation 
of the individuals of greatest interest for our questions. Nearly three-fourths of 
our sample self-identified as Black. Nearly ninety percent did not live in an urban 
community. In addition, an unfortunately large proportion of participants denied 
working full-time or being able to work. Participants were heterogeneous 
regarding sex and age. They were also unexpectedly diverse regarding markers of 
socio-economic status, such as education or income. This last observation, which 
will be discussed later, may have significant effects on the bivariate associations 
and external validity. 
Our sample was recruited from three different sites at approximately equal 
distributions. Bias of results from individual sites is less likely, but overall 
characteristics of the three recruitment sites may influence the results through 
selection bias. This will be elaborated upon later. 
Concerning HIV I AIDS, the respondents reported high levels of medical care. 
They also reported rather uniform perspectives of HIV I AIDS medical care. These 
observations may reflect a certain degree of trust in the medical community. 
They may also reflect more wide-spread understanding of the importance of HIV 
care in their disease progression. If the above are true, they may influence the 
results and also affect external validity. There was wide variation regarding 
duration of HIV diagnosis, but most respondents reported 12 or fewer years. 
This sample reports diverse past clinical research experiences. This suggests that 
overall bivariate associations are less likely to be biased by respondents' 
experiences in past clinical research. There are some observations, however, that 
may be closely associated with past research experiences. Our small sample size 
precludes precise or accurate analysis of these relationships or statistical 
adjustments for them. It does, however, permit cautious inference and hypothesis 
generation for future, more well-powered analyses. 
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Several variables were recorded to assess perspectives about clinical research. 
Some of these, such as perceiving transportation as a barrier, show wide variation 
in responses. This variation may in part be explained by associations with one or 
several characteristics. Multivariate associations, though not explored for this 
small sample, cannot be dismissed as unimportant in explaining these variations. 
Clinical research perspectives displaying less variation, such as the desire to help 
future HIV patients, may be more representative of this population as a whole. 
The small sample size and limited geographic distribution of our participants does 
not permit wide-spread generalization, however. In spite of this limitation, the 
characteristics with relatively homogenous responses may suggest local, and 
perhaps regional, perspectives that are more commonplace than those 
characteristics with more profound variation. 
Bivariate Findings 
Demographics 
Among demographic characteristics, only recruitment site was significantly 
associated with past research participation. This is plausible and expected given 
the characteristics ofthe recruitment sites. In particular, the GCRC's chief 
purpose is conducting clinical research. Thus, participants from this site would be 
expected to have a higher rate of past research experience than those from the 
other two sites. 
The significant association of recruitment site and the outcome introduces strong 
intraclass correlation into our analyses. While this is discussed in detail when 
addressing the appropriateness of our study design, it is important to note that 
adjustments were not made for the intraclass correlation in these analyses. 
Calculation of robust standard errors or estimation of multivariate analyses was 
not possible with three clusters and 47 participants. Stratification by recruitment 
site would have also rendered most, if not all, of the bivariate associations non-
significant. This latter option would also add little to our interpretations. 
The most important consequence ofintraclass correlation involves inflation of the 
type I error. Thus, a significance of 0.05 may in fact represent a much higher 
probability of a falsely significant association. Therefore, caution should be 
emphasized in all interpretations of bivariate results. Exact p values were 
reported to facilitate cautious reasoning. 
Lack of significant association of past research participation with sex and age 
were not expected. This investigator thinks that differences in respondent sex or 
age could have plausible effects on one's decision to participate in clinical 
research. Younger individuals could conceivably perceive fewer barriers, such as 
trust, to research participation. Roles and responsibilities that differ by sex could 
also affect decisions to participate in research. The small differences seen in this 
sample may in fact be larger and/or achieve statistical significance among larger, 
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more representative samples. Alternately, common perceptions of clinical 
research in this sample may be widespread enough to override differences of sex 
or age. 
There was very little diversity among our sample regarding residence in a rural 
community and race. Therefore, these variables were not expected to have 
sufficient variation to demonstrate meaningful differences in the outcome. Had 
our sample represented more diverse race and rural characteristics, however, it is 
very plausible that past participation would have significantly varied by these 
characteristics. 
Socio-economic Status (SES) 
Education, annual income, and insurance type were significantly associated with 
clinical research participation. These are plausible and reflect observations seen 
in other published studies. There were also meaningful differences in past trial 
participation according to receipt of public aid, full time employment, and 
inability to work. Their non-significance may reflect a weaker association with 
the outcome, but this difference may also show statistical significance in larger 
samples. These markers of SES, however, all reflect a consistent pattern. Those 
of higher SES have higher rates of past participation. It is possible that these 
associations are not reflections of differences in intelligence or altruism, but 
instead reflect greater exposure, access to, and trust in health care and health care 
professionals. Higher achievement may also favor an increase in inter-ethnic 
relationships, which may mitigate some amount of the distrust commonly seen in 
minority populations. 
Although the patterns seen for the SES characteristics appear consistent, it is 
important to note that theoretically, respondents may have felt pressure to report 
higher markers of SES. This would bias an association between SES and past 
trial participation away from the null hypothesis. More objective sources for 
these measurements, such as tax records, would make this bias less likely. 
Despite this possibility, my suspicion for this bias is low. 
HIVIAIDS Experiences 
Length of time since HIV diagnosis was significantly associated with the 
outcome. This was not an expected association, but it does seem plausible. 
Those diagnosed in the more distant past may have had vastly different 
HIV/AIDS experiences than those more recently diagnosed. Differences in such 
experiences could cause those more remotely diagnosed to be more reluctant to 
participate in clinical research. 
Large differences in past trial participation were also seen according to whether 
one was currently on HIV medications and whether HIV medications were 
considered worth taking. These differences were not statistically significant, but 
are clinically important and may have been significant in a larger sample. These 
characteristics may actually serve as proxies for trust in the healthcare field, 
specific providers, or research personnel. Adjushnent for these characteristics, 
however, may have mitigated this association. 
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It is also possible that respondents reported certain answers, such as HIV 
medications being not worth taking, less often because they were socially 
undesirable. This would certainly bias the results away from our null hypothesis. 
Since this can not be ruled out with any certainty, recognition of this possibility is 
important when drawing conclusions. 
Clinical Research Experiences 
Positive report of having been asked to participate in clinical research is 
significantly associated with past participation in clinical research. Aside from 
the intuitiveness of this association, it may additionally confound many of our 
associations. Those who have been asked may be very different from those who 
have never been asked. If so, then the validity of including both groups in this 
sample may be limited. Future analyses should focus on exploring the 
heterogeneity of these two groups. Findings may further inform us about trial 
participation patterns among minority populations. 
Clinical Research Perspectives 
Trust in clinical researchers was not significantly associated with past 
participation. Higher trust scores do appear, however, to reflect higher past 
research participation. Lack of a significant associaiton is in conflict with our 
hypothesis and current scientific literature. The predicted difference in trust 
according to past research participation was sizable and may have achieved 
statistical significance in a larger sample. 
The equal distribution of socio-economic status (annual income and education) 
among our sample may account for the higher values of trust seen in our sample. 
Inclusion of more highly educated individuals than is representative of the source 
population could bias the trust scores upward across both past research 
participation strata. Respondents may have also been less willing to report 
socially undesirable responses, such as low trust. Verification of this result in 
larger samples of rural minorities is needed to further clarify the presence of an 
association. Such future analyses should also be sufficiently powered to adjust 
for SES. 
Family persuasion to participate in clinical research was significantly associated 
with having participated in clinical research. Those for whom family persuasion 
was a major reason reported past participation far less than those for whom it was 
not a major reason. This result was unexpected, but may reflect a concern for 
confidentiality in research participation. If all had equal confidentiality concerns, 
the difference in their past trial participation may in fact lessen or disappear. 
Those for whom "not having a better option for obtaining HIV medications than 
to participate in clinical research" was a major reason for research participation 
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were predicted to have participated significantly less than those for whom it 
wasn't a major reason. Those who report it as a major reason, however, may in 
fact have less trust and be less well connected with the health care field. 
Accounting for these factors may eliminate this difference. Alternately, some 
respondents may have been unwilling to report this as a major reason to avoid 
social discomfort. If so, their responses would bias the results away from the null 
hypothesis and therefore account for the difference seen. 
Meaningful differences in past trial participation that were not statistically 
significant were reported for perception of transportation as a barrier to 
participation, current likelihood of research participation, wanting to help future 
HIV patients, and wanting to be a part of research. Larger sample sizes may 
actually show statistically significant differences for all of these associations. 
Perception of transportation and current likelihood of participation may also be 
confounded by SES and trust, respectively. 
The possibility of medical benefit for self as a major reason for research 
participation showed very little variation according to past participation. A more 
well-powered study will likely not change this result. Interpreting this non-
significant association as is suggests that it is not an important factor in this 
sample. This result may, however, represent social aversion to reporting this 
motive, which could bias results towards the null hypothesis or even in an 
opposite direction-those reporting no having higher participation rates. 
t--
Discussion of Results in Regard to the Existing Scientific Literature 
Although there are many scientific papers which discuss barriers and/or 
facilitators to clinical research participation, very few examine past or current 
willingness to participate as an outcome. Seven papers that fulfill this criterion 
'II b fi d · d · · h I 49 51 s2 54 59·62 WI e re erence m regar s to comparisons WJt our resu ts. · · · ' 
Demographics 
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Recruitment site was the only demographic variable significantly associated with 
past trial participation in this sample. This was expected because of the different 
characteristics the three sites. Specifically, the UNC General Clinical Research 
Center is expected to have a patient population with much more experience 
regarding clinical research than the average outpatient clinic. Similar associations 
have been reported in two cross-sectional studies (Table 14).54· 63 Advani and 
colleagues found willingness to participate in a clinical trial to be dependent upon 
clinic site. Stone and colleagues do not explicitly report an association between 
clinic site and participation, but they do adjust for clinic type in their multivariate 
analyses. Both suggest that characteristics of study or recruitment sites may be 
related to the outcome and potentially bias other associations. When planning 
small studies or using only a few recruitment sites, the choice of these sites is 
even more important. The ability to control or adjust for site characteristics may 
be limited or impractical in these situations. 
Age was not statistically associated with past research participation, but does 
appear to increase with nonparticipation in this sample. Shavers and colleagues 
and Tello and colleafues both present findings that mirror this finding (Table 
12)(Table 16).51• 52• 6 Corbie-Smith and colleagues, however, report a similar 
non-significant age association among black women, but a significant association 
between age and participation among white women and black and white women 
combined (Table 17).49 These suggest that greater age may be a deterrent to 
research participation, but perhaps more so for whites than blacks. The smaller 
sample of black women may have also limited power to detect a difference. 
Other studies among racially diverse samples similarly show greater age as a 
deterrent to research participation (Table 18).61• 63 Our results suggest a similar 
pattern, but this analysis may lack the statistical power to detect a difference 
among so few participants. Age may also be less of a deterrent for black 
populations than more ethnically diverse populations. 
For this study, racial/ethnic group was not related to past clinical research 
participation. This is in contrast to much of the existing literature, but is expected 
given the racial homogeneity of our sample. Several studies have shown blacks to 
be less willing to participate in research than whites (Table 14)(Table 18). 54• 61 • 63 
In addition, blacks appear to differ from whites regarding their characteristics 
associated with participating-or not participating (Table 12)(Table 17)(Table 
19).49• 51 • 6° For example, blacks' participation in research may be more associated 
with joining HIV vaccine trials to reduce their HIV risk behavior and for personal 
benefits such as free HIV testing, counseling, financial reimbursement, medical 
care, or current information on HIV, than white participants.60 Thus, our non-
significant result regarding race and past research participation is a reflection of 
the study design more so than actual respondent characteristics or responses. 
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Sex was also not a significant predictor of past research participation in our pilot 
data, but does show more men participating than women. The current literature is 
conflicting regarding the significance of sex in predicting research participation 
among African Americans. Shavers and colleagues report no significant overall 
association between sex and willingness to participate in a medical research study 
(Table 12).51 ' 52 This finding remained non-significant when stratified by race, but 
the lower willingness of males among white respondents appears clinically 
relevant and approaches a significant alpha level (p=0.09). Tello and colleagues 
also nonsignificantly report men as less willing to participate (Table 16).62 In 
contrast, Stone and colleagues report women as significantly less likely to 
participate than men in a sample of -40% blacks and -30% whites (Table 14).54 
This difference was not significant when adjusted for age, education, and clinic 
type. The higher educational level of Shavers' sample may account in part for her 
statistically non-significant result. 
Despite this scientific uncertainty, it is historically well known that women have 
been under-represented in clinical research. Furthermore, women may have 
different reasons for choosing to participate in clinical research. Colfax and 
colleagues reported women to be significantly more likely to participate in an 
HIV vaccine trial for protection, to reduce high risk behavior, and for composite 
personal benefits, such as free HIV testing, counseling, and financial 
reimbursement (Table 19).60 Women's. differing societal status as compared to 
men provides ample opportunity for differences in research participation 
behaviors. These societal differences may have important effects on research 
participation, which may also be associated with the type of research, the 
environment, and the risks involved. 
Urban or non-urban residence was also not statistically associated with past 
research participation, .bl!t does display a clinically important difference. Urban 
individuals appear to have participated nearly twice as much as non-urban 
residents. This was expected given that rural communities may have fewer 
research resources than urban communities. 64 In addition, physicians practicing 
in rural areas may be less likely to know of clinical research opportunities or to 
provide such support through their practice. The burden of seeking these services 
can result in reduced income from lost work, lost time, and costs associated with 
travel. I was unable to find articles examining an association between rural or 
urban residence and research participation. I believe, however, that the lack of a 
significant association in this data analysis is due in part to limited statistical 
power and few urban residents in our sample. This clinically relevant difference 
according to urban residence should be followed up in a larger sample to further 
explore this possible association. 
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Socio-economic Status 
Markers of socio-economic status (SES) are consistently associated with research 
participation in the scientific literature. Of annual income, receipt of public 
assistance, employment status, educational level, and insurance type, only annual 
income, education, and insurance type were statistically significant in this pilot 
study. 
Education is consistently reported in several studies as associated with clinical 
research participation (Table 12)(Table 18).51• 59• 61 In these references, higher 
education is associated with a higher likelihood of research participation. This 
pattern persists for Shavers & colleagues' work when stratified by race, but does 
not remain significant for blacks. This may be because of the few numbers of 
respondents in the lowest educational categories for this study. Higher education 
appears related to higher participation rates among 97 black women in the work 
of Corbie-Smith and colleagues also, but is similarly non-significant (Table 17).49 
Given the low alpha level reported for our educational association and the trends 
seen in the current literature, higher education is likely a significant predictor of 
research participation. 
Income appears less commonly reported as an SES variable for our relevant 
studies, but Advani does report it as significantly associated with participation. 59 
Shavers, however, does not report a significant association for her overall sample 
or when stratified by race. It is likely that does predict research participation, but 
not as well as educational level. Educational level may approach the underlying 
concepts or themes of SES more closely than income. 
There were no available studies with which to compare our results regarding 
insurance type, receipt of public assistance, or employment status. Similar to 
income, however, these variables all likely provide at least some predictive value 
for research participation, but perhaps not as well as education. 
A more appropriate question given these findings is why higher SES is associated 
with increased clinical trial participation? It is likely that those of higher SES 
may be more equipped to overcome, or are less vulnerable to, social, cultural, 
regional, and economic barriers regarding the health care system. Specific 
reasons or motivations for research participation may also vary according to SES 
and likely play some role in the decision making process. For example, Colfax 
reports that those with higher educational levels may be less likely to participate 
in an HIV vaccine trial to reduce their risk behaviors or for personal benefits. 60 
Differences such as these may further illuminate how to overcome minority 
under-representation in medical research. 
HIVIAIDS Experiences 
There are few available articles that address HIV I AIDS experiences and their 
possible association with research participation. Stone and colleagues report 
progression to AIDS as significantly associated with research participation (Table 
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14).54 CD4 count:<: 200 also seemed associated with increased participation, but 
was not statistically significant. Those ever tested for HIV -1 were significantly 
more willing to particiEate in a vaccine trial in a study published by Tello and 
colleagues (Table 16). 2 The characteristics measured in this sample, such as the 
time since diagnosis, being currently on medications, and reporting HIV 
medications as worth taking, can be seen as proxies for HIV severity. In this 
light, being currently on medications and considering them worthwhile agree with 
Stone's findings, while length of time since diagnosis does not. This last 
disagreement may be a reflection of younger age in those more recently diagnosed 
or a generational change in other characteristics, such as trust-the more recently 
diagnosed may have more trust. 
These variables may also be viewed, however, as proxies for trust or comfort with 
the health care system. Those who were recently diagnosed, who consider their 
medications worth taking, or who are on medications may interact with the 
medical system better or differently than their counterparts. This latter 
perspective appears synergistic with that of disease severity-its relationship to 
past research participation is similar. As such, the relative contribution of each 
perspective to our results cannot be teased out. Fortunately, more specific 
questions were asked regarding trust. In short, more recent diagnosis, currently 
taking HIV medications, and considering HIV medications as worth taking appear 
to reflect high participation rates. 
Clinical Trials Experience 
Individuals' experiences regarding clinical trials can have important implications 
on their subsequent participation. For this study, only past invitation to 
participate and past participation itself were measured. These two were very 
strongly related. There were no articles to compare this to, but Advani and 
colleagues do compare invitation to participate in research according to race. 59 
They saw no difference between African Americans and Whites. 
Research experiences may also include knowledge about clinical research. Two 
cross-sectional studies which assess respondents' knowledge report interesting. 
associations. Shavers and colleagues report that knowledge of the Tuskegee 
Syphilis Study was not associated with research participation (Table 12).' 1 The 
effect of that knowledge on trust in medical researchers, however, was related to 
willingness to participate in medical research. Those who lost trust in researchers 
were much less likely to participate than those with unchanged or increased trust 
in medical researchers. This is an example where the knowledge appears to not 
be important. 
In another cross-sectional study, Advani reports that those with knowledge of 
clinical trials as "experiments" on people and knowledge of research participants 
as "guinea pigs" were significantly less likely to participate in medical research. 59 
Alternatively, positive knowledge about research, such as the collection of more 
information on a therapy, possible societal or personal benefit, or simply knowing 
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someone else who has participated, was significantly associated with increased 
willingness to participate. This example highlights the importance of knowledge 
as part of the respondents' experiences. 
The significant association of clinical trial experience with willingness to 
participate in clinical research can cause difficulty in drawing conclusions in 
cross-sectional studies. Without follow-up, one can not know if the factor of 
interest is causal or whether past or current experiences, such as those pertaining 
to clinical trials, are causing the association. Recognizing this may lead to new 
research questions. In reference to this data set, the difference (if any) between 
those who have and have not been invited to participate in medical research is of 
particular interest. 
Clinical Research Perspectives 
Although many variables were measured for respondents' perspectives regarding 
clinical research, only family persuasion to participate and not having a better 
option for obtaining HIV therapy were statistically associated with past research 
participation. Trust in medical researchers, transportation as a barrier to 
participation, current likelihood of trial participation, wanting to help future HIV 
patients, and wanting to be a part of research also show patterns suggestive of a 
relationship, however. 
Although not significant, those with higher trust scores appear more willing to 
participate in research in our sample. Lower measures of trust have been 
previously associated with African American etlmicity, but have not been studied 
in relation to willingness to participate as comprehensively (Table 13).53 As 
mentioned previously, Shavers and colleagues reported that decreases in trust 
resulting from knowledge of the Tuskegee Syphilis study were significantly 
predictive for non-willingness to participate in medical research (Table 12).51 
Buchbinder and colleagues also report African Americans as citing mistrust of 
government and drug companies as reasons for refusing participation much more 
often than Whites, though statistical tests were not performed.61 Stone and 
colleagues show a non-significant difference in fear of experimentation-a proxy 
for trust-between persons of color and whites. 54 The pattern seen in our results 
and the literature suggests that trust is associated with willingness to participate in 
medical research. This association needs to be tested in a larger study, however, 
to prove its validity. 
Transportation is a conceptually expected barrier to research participation among 
rural populations. Few quantitative studies, however, have assessed this. Our 
results show that those denying transportation as a problem participated more 
often. Both Advani and Buchbinder report similar, but statistically non-
significiant, findings (Table 12)(Table 18). 5 ~· 59• 61 Although transportation is 
likely an important determinant in rural populations, confirmation in a larger 
sample is necessary for definitive conclusion drawing. 
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Current willingness to participate appears positively correlated with past research 
participation in our results. Buchbinder similarly reports that those with past 
willingness to participate enrolled in their study at higher rates than those less 
willing in the past (p<O.OOl) (Table 18).61 Although both associations seem valid, 
repetition in a larger study is definitely warranted. In addition, it is noteworthy 
that past willingness is not a great tool for use in recruitment. Both our results 
and, more appropriately, Buchbinder's results, show that relatively small 
percentages of those who indicated past willingness actually participated at the 
time of enrollment. · 
Despite statistical non-significance, several reasons for participating research 
appear related to past participation in studies. In our results, wanting to help 
others with HIV and expecting medical benefit for self appeared related and 
unrelated to past participation, respectively. These are supported by papers by 
Advani, Shavers, and Colfax (Table 12)(Table 19),52• 59• 60 Our results concerning 
family influence on decision to participate appears similar to those presented by 
Advani. 59 Wanting to be a part of research was not assessed in any of the 
available literature. 
Lastly, those for which not having a better option for obtaining HIV therapy was 
not a major reason for participating in research participated more. than those for 
whom this was a major reason. None of the available studies compared these two 
characteristics. Several did, however, report how significant of a facilitator this 
was for participating. Shavers and Advani report it as a very important factor 
among their samples (Table 12).52· 59 Colfax and colleagues, however, report that 
< 10% of men and< 30% of women in their sample agreed that receipt of medical 
care was an important motivator for their research participation. The overall high 
risk for HIV within this latter sample, however, may account for this difference in 
motivation. 
Discussion of Analysis Plan 
Choice of Outcome Measure 
Choosing an outcome for this data analysis proved very difficult. The two most 
compelling options for an outcome were past clinical trial participation and 
current willingness to participate in a clinical trial. 
Past trial participation was measured in all respondents via the structured 
interview. It was recorded as a binary variable, "yes" or "no." Of those who 
responded no, many had also never been asked to participate. The past trial 
participation variable may therefore actually represent three possible responses: 
42 
Never asked, asked but not enrolled, and enrolled. The former two categories 
were condensed into the "no" response, however, for practical purposes. Such a 
small sample may not have had adequate power to discern between three outcome 
categories. Investigating the role of being previously asked to participate would 
be better served in the context of a larger sample size. 
Current willingness to participate in a clinical trial was measured in those who 
had never enrolled in a clinical triaL Use of this variable for the outcome would 
have required 
restricting the sample to the 28 who were asked, assuming that the remainder of 
the sample are currently somewhat or very likely to participate, allocating 
responses to the 19 via some previous estimate of willingness, or randomly 
allocating responses for the 19. 
Past trial participation was a better choice firstly because all participants were 
asked this question, as compared to current willingness. For current willingness, 
restricting to only 28 respondents would have compromised statistical power. 
Alternately, assuming current willingness for the 19 may have artificially inflated 
the number of cases and ignores possible contributions of past research 
experiences to their current willingness. This could bias all of the bivariate 
associations towards or away from the nulL The unavailability of estimates for 
current willingness in those who have previously participated prevented allocation 
of these responses on objective evidence. Finally, randomly allocating the 
responses for 40% ofthe sample may have biased results to the nulL This may 
also ignore the contribution of past clinical trial experiences to current willingness 
among the 19 individuals. In lieu of compromising statistical power, introducing 
concerns of confounding, or potentially biasing the results, past participation was 
chosen for its less profound measurement bias and confounding issues. 
Past trial participation is theoretically dependent upon actually being asked to 
participate. Only 51.1% of this sample had ever been asked. Although whether 
one was asked to participate in a trial confounds the bivariate relationships, there 
were several options available to deal with it. Restriction or stratification of the 
non-past trial enrollees to only those who had been previously asked would 
reduce the already small sample size and therefore decrease the statistical power 
43 
to detect differences in the outcome. Modeling with logistic regression could also 
account for this covariate. Tbis was precluded, however, by the small number of 
independent variables allowed in the modeL The negative responses to this 
covariate also predict the outcome perfectly. Tbis latter violates an essential 
assumption of logistic regression and prevents its use. A final option is simply 
reporting the unadjusted bivariate associations. This of course requires reporting 
the relationship of the covariate to the outcome, but recognizing that the sample 
size is too small to estimate its contribution. 
In short, past trial participation was chosen for its completeness, less concern for 
measurement bias, and its partial, though inadequate, potential for adjustment 
with restriction or stratification. 
Analysis Plan 
The quantitative analysis plan used for this secondary data analysis was designed 
to be exploratory in nature. Exploratory analyses were more appropriate than 
testing theoretical hypotheses because of the very small sample size. Small 
samples may not be representative of the larger population. Therefore, any 
statistically significant results are generalizable only to that sample. For this 
reason, small samples are generally used for hypothesis generating. Associations 
or patterns may be used for developing or refining subsequent hypotheses and 
tested in larger, more representative samples. With this goal, univariate and 
bivariate analyses were ideal for characterizing this sample. 
Statistical power was also a very relevant limitation when constructing the 
analysis plan. For multivariate analysis, the binary outcome required logistic 
regression. Previous estimates of one independent variable for each I 0 cases of 
the outcome would have limited models to two independent variables for 19 
cases. Two independent variables were adequate to adjust the bivariate results for 
one potential confounder, but prevented estimation of a larger modeL 
Strengths/Weaknesses 
The statistical methods used for this study are strong and appropriate. The 
continuous variables were appropriately examined for a normal, linear 
relationship to the outcome before choosing parametric statistical tests. Non-
parametric tests were used when the above was not present or in question. 
Comparisons of categorical variables used Fisher's Exact test instead of Pearson's 
Chi Square test when an expected value in any cell was very small ( < 5). All 
statistical tests were also two-tailed with a 5% alpha level and 80% power. 
This data analysis was, however, limited by its study design. The small sample 
size firstly limits more detailed analyses of associations within this sample. 
Estimation of a multivariate model for all characteristics associated with the 
outcome was not possible. Simultaneously controlling for more than one 
covariate was also not statistically appropriate. 
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Secondly, the choice of recruitment sites for this study imposes significant 
intraclass correlation from upon the results. Large intraclass correlation, as seen 
in this study, can inflate the alpha level such that falsely concluding a statistically 
significant result becomes more likely. Furthermore, statistically adjusting for 
the intraclass correlation was not possible in such a small sample. Although I 
considered stratifying by site or lowering the significance level, I ultimately chose 
to simply present the data for what they were-pilot data-and subsequently draw 
cautious inferences regarding the patterns seen. By reporting the exact p values, I 
hope to provide the reader with enough information to critically examine my 
conclusions and make their own inferences. 
The results reported for this study have fair potential to be affected by 
measurement bias. While all parameters were measured and recorded 
consistently by trained staff, some questions may have been perceived as socially 
sensitive. If so, then respondents may have felt pressured to report more socially 
desirable answers, such as higher trust in researchers or not perceiving medical 
benefit for self as a major reason to participate in research. This is a common, but 
often unavoidable limitation to social science research. 
There may also be fair potential for selection bias in this study. Eligible patients 
were identified non-randomly and may have been very similar within recruitment 
site. It is unknown how exactly this might bias our results, but a more non-
systematic method of recruitment would have minimized this possibility. The 
inclusion of more sites may have further mitigated the potential for selection bias. 
Given the concerns regarding selection bias, measurement bias, and study design, 
the internal validity of this study is fair. The weaknesses presented are enough to 
cause some concern, but not sufficient to consider the entire study invalid. 
Furthermore, this study has very limited external validity. Generalizations can 
only be made to the recruitment sites from which the participants came. Their 
non-random selection and small sample size limit generalizations to larger 
populations. Even so, the results presented here remain important. They provide 
important preliminary information regarding clinical research behaviors and 
outlooks among rural minorities, a population not often studied for HIV/AIDS. 
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Conclusions 
Demographics 
In this analysis of 47 rural minorities, ~40% reported past participation in a 
medical research study. Among this 40%, males appeared to participate more 
often than women. There is some support for this association in the literature. 
This may be a reflection of women's historical exclusion from medical research. 
There may also be important differences in the reasons for participation between 
men and women. 
Older age appears to be associated with lower participation in research. This is 
supported by the literature, although age may not be as strong of a predictor 
among blacks as it is among whites. 
Recruitment site was significantly associated with past research participation. 
Furthermore, recruitment site characteristics are very important when planning a 
study. When possible, care should be taken that site characteristics are not 
strongly associated with important outcome or predictor variables. Such 
associations may be adjusted for in larger studies, but are very troublesome in 
smaller samples. 
Urban participants appeared to enroll in research studies more often than non-
urban participants. Though not statistically significant or verified in the literature, 
this observation does address an original question and provide important clues 
regarding future analyses and possible results. 
Race is an important predictor of willingness to participate in medical research in 
the scientific literature. These usually involve comparisons of black and white 
populations. Our sample did not detect a difference between blacks and non-
blacks, but also only had one white participant. Therefore, our results suggest 
little difference in research participation between blacks and other ethnic 
minorities. 
Socio-economic Status 
Socio-economic status (SES) is an important predictor of research participation in 
our stndy and in the literature. Although several specific variables appeared 
significant, education may be the strongest predictor among those we measured. 
HIVIAJDS Experiences 
HIV I AIDS experiences show an association with research involvement, but may 
be reflective of two underlying themes. Firstly, the sickest may be more likely to 
enroll in studies than the less sick. The exception here, however, is the 
respondents' length of time since being diagnosed. Those more recently 
diagnosed appear to participate more than those diagnosed less recently. This 
may be because the introduction ofHAART has weakened the association 
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between length of HIV diagnosis and disease severity. Also, the more recently 
diagnosed may reflect a generational increase in trust regarding medical research. 
The second underlyingtheme is that HIV/AIDS experiences may serve as proxies 
for trust or comfort with the healthcare system. Our trust scale, however, would 
likely serve as a much better indicator for this theme than HIV I AIDS experiences. 
For future analyses, more narrow definition ofHIV/AIDS experiences to measure 
only disease severity may be more useful. 
Clinical Trials Experiences 
Various clinical trial experiences show associations with research participation in 
our study, but more so in the literature. These associations are of particular 
interest because they may confound our other bivariate relationships. Because of 
their basic relationship to our outcome, questions regarding their role in deciding 
to participate in clinical research may lead to new and equally important research 
questions and hypotheses. 
Clinical Research Perspectives 
Though not statistically significant, the pattern between trust in researchers and 
past research emollment in our study parallel the results cited in several scientific 
publications. Larger sample sizes may be needed, however, to better assess its 
importance. 
Considering transportation as a major barrier to research participation was 
statistically non-significant when assessed with past research participation. It did, 
however, show participation to be higher among those who didn't consider 
transportation to be a barrier. The importance of transportation has not been 
widely addressed in the literature, as was the case with urban/non-urban 
residence. These both represent novel findings, however, that are adequate to 
support future, more well powered investigations into their significance. 
Past participation in research relates well to current willingness to do so. 
Similarly, the literature shows past hypothetical willingness to be associated with 
"current" decision to emoll in a research study. These both suggest a permanence 
of perspective over time with regards to willingness. They both also show that 
past estimates of willingness are imperfect and not to be used for actual 
recruitment methods. 
Non-perception of family persuasion as a major reason and perception of not 
having a better option for obtaining HIV therapy as a major reason for research 
participation were both significantly associated with past research emollment. 
These were both also supported in the literature. The increased participation 
among those not considering family persuasion important may reflect a need or 
desire for confidentiality regarding their HIV and any associated treatments, care, 
or research participation. Aversion to socially undesirable answers may account 
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for the high participation rates among those denying using research for obtaining 
HIV care. 
Wanting to help future HIV patients and wanting to be a part of research were not 
statistically significant in their association with past research participation, but do 
show meaningful differences. The association with wanting to help future HIV 
patients is supported in the scientific literature. Denial of the importance of this 
altruistic motivator, however, may have been under-reported due to social 
pressures. Wanting to be a part of research was not assessed in the literature, but 
may similarly be perceived as altruistic and therefore difficult to report as un-
important. 
Lastly, medical benefit for self showed no meaningful difference or significant 
association with past research participation. Similar findings are seen in the 
scientific literature, but are subject to social pressures. Many respondents may 
have felt this to be important, but were afraid to report it so. 
ID: 
Date: 
Appendix I. 
Location: ____ _ Time Start: 
Persons Living with IllV I AIDS Interview Gnide 
Screening Cover Sheet 
[Read information sheet to respondent or give them time to read it themselves. 
Leave copy with them] 
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We appreciate your time and participation in helping us learn more about persons living 
with HIV/AIDS. We are interested in learning more about your experiences with clinical 
research. In an effort to better understand your experiences, this survey will ask questions 
about your experiences living with HIV I AIDS and your experience with clinical trials in 
HIV I AIDS research. 
***Important: For GCRC Participants, please have them first check in for our 
protocol, #2186, if they are willing to participate.*** 
Because we ask you a lot of in-depth questions, we like to tape record the interviews so 
we don't miss anything important that you say. Your name will not be anywhere on the 
tape. If you want me to stop the tape at any time, you can just let me know. Is it all right 
to tape the interview? 
D 1 Yes 
Do No 
***[lfYes, Start Tape Recorder Now]*** 
The following brief screening questions will help me to determine which survey will 
apply to your experiences while making the best use of your time during this interview. 
[Interviewers will use answers to following questions to determine which color 
interview guide they will use] 
Sl. Have you ever been asked to be in a clinical trial for HIVIAIDS treatment? By 
clinical trials we mean research stndies that are being done to find out the best 
combinations of drugs for treatment oflllV. 
Do If no, please proceed to the pink survey 
D 1 If yes, please proceed to question S2. 
S2. Have you ever taken part (enrolled) iu any clinical trials? 
Do If no, please proceed to the blue survey 
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0 1 If yes, please proceed to the green survey 
Clinical Trials 
Appendix II. 
Interview Guide for people who 
did not enroll in clinical trials 
(Blue Version) 
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First we have a few questions about your understanding of clinical trials. By clinical trials 
we mean research studies that are being done to find out the best combinations of drugs 
for treatment ofHIV. 
1. What have you heard about clinical trials for IllY/AIDS? 
Probes: 
a. Have you ever heard of any trials for HIV/AIDS? 
b. What do you think they are? 
c. How would you explain it to someone who had never heard of it? 
You told us that you have been asked to participate in at least one clinical trial, but that 
you did not take part in any trials. For the next several questions, please think about the 
most recent study you were asked to take part in. 
2. How did you first hear about the study? 
3. What were your reasons for not taking part? 
4. What, if anything, would have made it easier to take part in this study? 
[Free List] 
5. What, if anything, were some fears or concerns you had about taking part in 
the clinical trial? [Free List] 
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6. What, if anything, sounded good about this study? {Free List] 
7. What, if anything, sounded bad about this study? {Free List] 
8. What would you tell a friend who was considering enrolling in a clinical trial 
about your experience hearing about this study? 
Now we have a few questions about HIV/AIDS clinical trials in general. Remember, by 
clinical trials we mean research studies that are being done to find out the best 
combinations of drugs for treatment of HIV. 
9. What do you think would make it hard for other people with HIV/AIDS to 
take part in clinical trials? {Free List] 
10. What do you think would make it easy for other people with HIV/AIDS to 
take part in clinical trials? {Free List] 
11. If you were asked to take part in a clinical trial now, how would you feel 
about it? 
Probe: Who would you talk to about being in a trial? 
12. How likely would you be to take part? 
0 1 Very likely 
0 2 Somewhat likely 
0 3 Somewhat unlikely 
0 4 Very unlikely 
13. Probes: 
If "very likely" to Q12: Why would you be very likely to take part? 
If "somewhat likely" to Q12: Why would you he somewhat likely to take 
part? 
If "somewhat unlikely" or "very unlikely" to Q12: Why wouldn't you be 
likely to take part? 
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14. I'm going to read a list of reasons why some people may decide to take part 
in a clinical trial. As I read each one, please tell me whether each of these 
would he a major reason, a minor reason, or not a reason you would take 
part in a clinical trial. 
Major Minor Nota 
Reason Reason Reason 
a. Trust in the doctor who referred you to the trial o, o, o, 
b. Trust in the doctor who would be taking care o, o, o, 
of you in a research trial 
c. Trust in the nurses who would be taking care of o, o, o, 
you in a trial 
d. Wanting to help futnre HIV patients o, o, o, 
e. The possibility of medical benefit to you o, o, o, 
f. Your family would want you to do it. o, o, o, 
g. Wanting to be part of research. o, o, o, 
h. Not having a better option for getting treatment o, o, o, 
for your HIV. 
15. Was there some other important reason not mentioned yet? 
16. Do you think you would get medical benefit from taking part in an HIV 
clinical trial? 
Probe for why/why not 
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17. Did you think you would get emotional benefit from taking part in a trial? 
Probe: That is, you would have a better emotional outlook 
18. Some people have told us that one reason they haven't taken part iu clinical 
trials at UNC is because they have to travel so far to get there. How much of 
a problem is that for you? Is that: 
D 1 A big problem 
0 2 Somewhat of a problem 
0 3 Not a problem at all 
19. If a van were to come out to your community to conduct clinical trials, how 
would you feel about that? 
Probe: 
a. How would you feel about getting on a van for medical services (e.g. 
drawing blood, getting medication ... )? 
b. Clarify if necessary: This will not be a van that is just for HIV I AIDS, it 
will have other services with it as well, such as blood pressure screening, 
so that no one would know why anyone was getting on the van. 
20. How likely would you be to take part in a clinical trial study, if a van came 
right to your neighborhood? (Read Choices) 
D 1 Very likely 
0 2 Somewhat likely 
0 3 Somewhat unlikely 
0 4 Very unlikely 
21. Probes: 
If "very likely" to Q20: Why would you be very likely to take part? 
If "somewhat likely" to Q20: Why would you be somewhat likely to take 
part? 
If "somewhat unlikely" or "very unlikely" to Q20: Why wouldn't you be 
likely to take part? 
54 
22. What do you think would be good ways for researchers to tell people about 
clinical trials? 
Probes: 
a. What would be good ways for them to get the word out? 
b. What would be most likely to work with you? 
HIV/AIDS experiences 
Now I am interested in knowing more about you and your experiences in being told you 
haveHIV. 
23. Tell me about when and under what circumstances you were told about your 
diagnosis? 
Probe if necessary: How long ago were you diagnosed? 
24. Tell me what you know about IDV. 
Probes: 
a. What it is 
b. How it is spread 
c. How it affects you 
d. How you need to care for yourself when you have HIV 
25. How about AIDS? 
Probes: 
a. What it is 
b. How it affects you 
26. In general, what do you know about medications for HIV? 
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Probes: 
a. Names? 
b. What they do? 
c. How much they cost? 
d. How often you have to take them? 
27. Are you presently taking any medications for HIV? D 1 Yes 0 0 No 
Probes: 
a. type of medication 
b. Frequency of taking 
c. Side effects or other problems 
d. How do they feel about taking this medication 
28. Are HIV/AIDS medications (also known as antiretrovirals) worth taking? 
Would you say: 
D 1 Definitely 
0 2 Probably 
0 3 Probably not 
0 4 Definitely not 
29. Why or why not? 
30. Are you presently taking any medications for HIV? 
a. Probe: type of medication 
b. Frequency of taking 
c. Side effects or other problems 
d. How do they feel about taking this medication 
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Trust 
Please tell me if you strongly agree, somewhat agree, neither agree nor disagree, 
somewhat disagree, or strongly disagree with each of the following statements: 
31. HIV researchers, in general, care about their 
study participants' health just as much or more 
as their participants do. 
32. Sometimes HIV researchers care more about 
what is convenient for them than about their 
participants' medical needs. 
33. HIV researchers are extremely thorough and 
careful. 
34. You completely trust HIV researchers' 
decisions about which medical treatments are 
best. 
35. HIV researchers are totally honest in telling 
their participants about all of the different 
treatment options available for their conditions. 
36. HIV researchers think only about what is best 
for their participants. 
37. Sometimes HIV researchers do not pay full 
attention to what participants are trying to tell 
them. 
38. HIV researchers always use their very best skill 
and effort on behalf of their participants. 
39. You have no worries about putting your life in 
the hands of HIV researchers. 
40. An HIV researcher would never mislead you 
about anything. 
41. All in all, you trust HIV researchers 
completely. 
Background 
Now I have a few questions about you: 
Interviewer: DO NOT READ 
42. What is Respondent's sex? 
0 1 Male 
0 2 Female 
43. Are you Hispanic/Latino? 
Strongly Somewh Neither 
Agree at Agree agree 
nor 
disagre 
e 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
01 o, o, 
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Somewh 
at 
Disagree 
o, 
04 
o, 
04 
o, 
04 
o, 
o, 
o, 
04 
o, 
s t 
D 
0 1 Yes 
DoNo 
44. What is your race? (Do NOT read choices, record all that apply.) 
0 1 Caucasian/White American 
0 2 African American 
0 3 Asian American 
0 4 American Indian or Alaska Native 
0 5 Native Hawaiian/Pacific Islander 
0 6 Other (please specifY) __________ _ 
45. How old are you? _____ _ 
46. What is the highest grade you completed in school? (Read choices, accept 
only one response) 
D 1 Less than high school 
0 2 Some high school 
0 3 Graduated from high school or GED 
0 4 Some undergraduate college or technical school 
0 5 Completed College 
0 6 Masters Degree 
0 7 Doctorate Degree 
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47. What best describes your employment situation at this time? That is, are 
you employed full-time, part-time, taking care of home or family, in school, 
retired, unable to work because of an illness or condition, or something else? 
(Please check all that apply) 
0 1 Employed part-time 
0 2 Employed full-time 
0 3 Taking care of home or family 
0 4 In school 
0 5 Retired 
0 6 Unable to work because of an illness or condition 
0 7 Something else (SpecifY) _______ _ 
48. What would you say your main occupation is or has been? 
DK 
REF 
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49. What, if any, kind of health insurance do yon have? (Read Choices) 
0 1 Private 
0 2 Medicare 
0 3 Medicaid 
0 4 Something else, (specifY) 
0 5 or None? 
0, DK (DO NOT READ) 
0 9 Refused (DO NOT READ) 
50. Would yon describe where yon live as: 
0 1 Rural 
0 2 Urban 
0 3 Suburban, or 
0 4 Something else? ________ _ 
0 8 DK (DO NOT READ) 
0 9 Refused (DO NOT READ) 
51. What town or city do yon live in? (Note to interviewer: If respondent wants 
to know why we need this, explain it is just so we can figure out how far they 
have to travel for care). 
52. Are you getting any public assistance, such as WIC, SSI, Disability, etc? 
0 1 Yes 
DoNo 
53. Looking at this card (HAND CARD) could you please tell me, before taxes, 
which one describes your household's total income last year: 
0 1 Less than $5,000 
0 2 $5,000 to Jess than $20,000 
0 3 $20,000 to less than $40,000 
0 4 $40,000 to Jess than $60,000 
0 5 $60,000 to less than $80,000 
0 6 $80,000 or more 
0 7 DK/NA [DO NOT READ] 
0 8 REFUSED [DO NOT READ] 
Thank you very much for your time. We really appreciate all of the time 
you gave us and your thoughtful answers. 
**Remember to give cash(food voucher** 
**Interviewers record a11 observations into tape after interview is over** 
TimeEuded: 
Income Categories Card 
0 1 Less than $5,000 
0 2 $5,000 to less than $20,000 
0 3 $20,000 to less than $40,000 
0 4 $40,000 to less than $60,000 
0 5 $60,000 to less than $80,000 
0 6 $80,000 or more 
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Year, Design Selection Bias Measurement Con-founding 
Study Bias 
Question 
Harawa, Serial Minimal/Moderate Moderate Moderate 1989-1990 Overall Quality: Fair 
N.T., cross- -Cum Prev -2% in all counties but 
Douglas, J., sectional -Seattle Clinic had -Used two -Large S.F. (9.3%) 
2004 Design sliding scale fees but different tests demographic -Cum Prev highest in those > 30 years -MSMs comprise a higher 
others had none (less over study differences in of age proportion of HIV burden in 
To study of a problem since period? (likely Table I, likely -Cum Prev highest for black MSW western states 
temporal they contribute the identical usage reflect regional -MSW and Women who !DU were 2- -Recent MSM prev is 
changes in least patients) across study differences and I OX more likely to have HIV comparable w/ prev in other 
epidemiology -Sampling times and sites makes this not selection bias Temnoral Trends U.S. regions 
ofHIV in durations varied by less of a -MSM data MSW -Reduction in Western 
STD clinics site problem) adjusted for age, -Prev declined at least 50% across all MSM prev has been less 
in 4 western , -30-40% of race, IDU status counties among Blacks than among 
urban U.S. those eligible -Clinic -Prev declined for all races (except Whites 
counties lacked a blood population shifts whites in Seattle) and IDU across all 
from 1989 to sample, -Difference in sites -Less generalizable for other 
1999. compared to clinic Women U.S. regions, general clinic 
<1 0% in other 3 presentation (care -Prev declined at least 30% across 3 patients, and STD clinic 
counties seeking) by race of 4 counties patients not having new 
(Seattle also had -Varying -Downward trend inconsistent across STD complaint or routine 
the least # of enrollment times racial groups STD evaluation 
patients, making and durations -Prev unchanged or increased in 
this less of a within and women >40 y.o. in L.A. and S.F. 
problem) between sites MSM 
-L.A. did not could influence # -Prev declined across all counties 
include all of cases detected -Prev decline not as large or 
public STD significant for Blacks 
clinics in study 
Table 3. Evidence Table for Calonge, Petersen, Miller, Marshall, 2003. 
Author, Year, Study Potential for Potential Potential for Important Conclusions 
Study Design Selection Bias for Con- Results 
Question Measureme founding 
nt Bias 
Calonge, Cross- Minimal Moderate Minimal -Overall Overall Quality: Good 
Petersen, sectional -Patients from -Dependent -Fewer men Seroprevalence 
Miller, A SPN database on assay- <30y.o. than 2.3/1000 -Fits in with existing literature 
Marshall, don't differ not for gen. (95%CI 1.3-3.3) of that time cited as ranging 
2003. substantially adequately population -Previously from 0.42-3.6/1000 in HIV 
from U.S. gen. discussed -More women Unrecognized prevalence among various 
To estimate population in >20y.o. than S eroprev. different risk groups 
the age or gender for gen. U.S. 1.0/1000 
seroprevalence -Variable population (95%CI 0.3-1.7). -Men's seroprev alence may be 
ofHIV-1 enrollment -For men <40 -57% ofmen under-estimated and women's 
infection in schedules by y.o., were previously seroprevalence may be over-
persons practice are fewer in unrecognized, estimated given sex 
seeking care (controlled for in sample than compared to 33% demographics in comparison to 
from primary analysis) in NAMCS of women NAMCS data. 
health care -93% of original population for -Men had 4X 
providers sample included general higher 
from June 1, in final analysis practicioners seroprevalence May not be generalizable to 
1989 to -Are only 
-For women> than women (4.6 broad clinic populations- only 
December 31, patients who had 20 y.o., are vs. 1.2 per I 000 populations whom have blood 
1990. blood drawn more in p-y) drawn 
-87% of patients sample than -4.5 vs. 1.3/l 000 Not generalizable to general 
White American in NAMCS p-y prevalence population b/c not all seek care 
(but likely population for non-rural vs. Not generalizable to those 
characterizes rural practices outside of age range 15-49. 
clinic 87% White study population-
population) may not generalize in other 
races 
Table 4. Evidence Table for Pincus. Crosby, Losina. et aL 2003 
.. 
Author, Year, Study Study Potential Potential for Potential for Con- Important Conclusions 
Question Design for Measurement founding Results 
Selection Bias 
Bias 
Pincus, Crosby, Cross- Minimal Minimal Minimal b/c -Total HIV Overall Quality: 
Losina, et al., 2003 sectional -36.5% -Measurement of although some prevalence Good 
enrollment cases dependent unequal 2.2% 
To determine rate (of all on test demographics, may (95%CI 0.9- -Demographics of study 
prevalence of acute screened at characteristics reflect 3.5) site similar to 72 other 
HIV infection among triage) -Used most characteristics of -AcuteHIV hospitals in the U.S. 
patients with -93.3% of sensitive assay target population prevalence -Prevalence of acute 
symptoms of a viral those for HIV detection -Unequal sex 1.0% and chronic HIV 
illness who presented deemed w/ no false (more men), race (95%CI 0.1- obtained for this study 
to an urgent care eligible were positives (more African 1.9) similar to results from 
center at an urban enrolled Americans), and -Chronic previous studies 
teaching hospital sexual practices HIV 
from March 30, 2000 (80% had any sex) prevalence 
to March 30, 2001. 1.2% -Not generalizable to 
(95%CI 0.2- those with no 
2.2) signs/symptoms of viral 
illness, to those w/o 
-Lowest risk factors, to general 
possible populations, to those w/ 
acute HIV chronic HIV infection 
prevalence is 
0.6% 
Table 5. Evidence Table for Coco and Kleinhans, 2005. 
Author, Year, Study Study Potential for Potential for Potential Important Conclusions 
Question Design Selection Bias Measurement Bias for Con- Results 
founding 
Coco and Kleinhans, Cross- Minimal Minimal Minimal Prevalence Overall quality: 
2005. sectional -Denominator -Measurement of Estimates Good 
includes patients HIV and of Fever 
To calculate a national with up to 3 symptoms 0.66% Not generalizable 
estimate of the symptoms consistent (denominator) (95%CI to those >54 y.o., 
prevalence of primary w I acute HIV and subject to quality of 0.53-0.92) federal, veteran, 
HIV infection for excludes those w/ data collection for Rash and military 
patients visiting symptoms less likely the NAMCS and 0.56% outpatient 
physicians' offices, to be HIV (ex. all 3 NHAMCS (95%CI facilities, and 
emergency departments, symptoms had to be databases 0.35-0.94) those w/ 
and hospital outpatient consistent w/ HIV) -Assumptions for Pharyngitis undiagnosed 
clinics with symptoms -Numerator numerator are chronic HIV 
consistent with primary accounted for% of reproducible and 0.13% infection 
HIV infection regardless all HIV accounted logical, but (95%CI 
of risk factors for the for in denominator, dependent upon 0.10-0.19) 
year 2000. %of cases w/ quality of data 
symptoms, % of supporting them 
cases who seek care -Great uncertainty 
in estimation of 
percentage seeking 
care, but sensitivity 
analysis done 
Table 6. Evidence Table for Smith, Gwinn, Selik, et al., 2000. 
Author, 
Year, Study 
Question 
Smith, D.K., 
Gwinn, M., 
Selik, R.M ., et 
al., 2000. 
To review the 
most current 
data on the 
extent of HIV 
infection and 
associated risk 
behaviors, the 
occurrence of 
AIDS, and HIV-
re\ated mortality 
in African 
Americans and 
suggest 
additiona) 
information, 
services, and 
intervention 
strategies to 
reduce HIV 
infection in this 
population. 
Study 
Desig 
n 
System a 
-tic 
Review 
Potential for 
Selection 
Bias 
Moderate 
-Used 
computerized 
search and 
reviewed 
references lists 
of papers 
-Description of 
search methods 
vague and 
incomplete 
-Did not ask 
experts for 
additional papers 
-Did not explain 
methods for 
acquiring 
unpublished 
data, but several 
such sources 
used. 
Potential 
for 
Measure-
ment Bias 
Minimal 
vMany 
different 
epidemiologic 
a! measures 
reported, but 
are important, 
meaningful, 
and consistent 
with 
objectives. 
Assessment 
& Weighting 
of Methodo-
logical 
Quality 
Very little 
vAppears data 
from papers only 
included if 
externally valid 
to U.S. Black 
HIV/AIDS 
populaiton 
Important Results 
HIV Incidence 1985-1991: Estimated 
Seroincidence of 51.1 vs. 3.7 per 100,000 p-
y for Black and White Americans, 
respectively. 
1998: 6346 and 5015 new HIV cases for 
Black & White Men, respectively. 
4230 and 1268 new HIV cases forB lack & 
White Women, respectively. 
HIV Prevalence 
l988vl994: Seroprevatence of 1.10% and 
0.20% for Black and White Americans l8v59 
y.o., respectively. 
1996: Seroprevalence for Black and White 
men age 16v21 are 0.22% and 0.04%, 
respectively. 
Seroprevalence for Black and White women 
age J6v21 are 0.35% and 0.07%, respectively. 
AIDS Incidence 
I 998: 
Black and White Americans were 45.1% and 
33.4% ofaH incident cases, respectively. 
H IV I AIDS Mortality 
1998: Estimated mortality rate of58.2 and 9.8 
per I 00,000 for Black & White men aged 25v 
44, respectively. 
Estimated mortality rate of25.6 and 1.9 per 
I 00,000 for Black & White women aged 25-
44, respectively. 
Census 
I 998: 
African American- 12% 
White American- 72% 
Conclusions 
Overall Quality: Fair 
African Americans 
have the highest HIV 
and.AIDS incidence, 
HIV prevalence, HIV 
mortality, and greatest 
number of years of 
potential life lost. 
Socioeconomic status 
does not entirely 
account for disparity in 
HIV/AIDS. 
Sexual networks may 
play a role in the 
disparate HIV 
transmission. More 
research is needed. 
More epidemiological 
studies are needed with 
generalizable 
samples and sample 
sizes sufficient for 
su banaly ses. 
Table 7. Evidence Table for Rosenberg and Biggar, 1998. 
Author, Year, Study Potential for Potential for Potential Important Results Conclusions 
Study Question Design Selection Measnrement for Con-
Bias Bias fonnding 
Rosenberg, P.S. and Back Minimal Moderate Minimal 1995: Black men and women Overall Quality: Fair 
Biggar, R.J., 1998. Calculation had highest incidence of AIDS 
to estimate -Only cases -Possible -Patient or ( 124 per I 00,000 and 60 per -Notable success in HIV 
To estimate trends in the reported to CDC misclassification physician 100,000 respectively). White prevention for white men 
HIV incidence and incidence are used- bias for mode of inappropriate! men and women had AIDS (50% reduction in 
prevalence in of infection corrected for this transmission y suspecting incidence rates of 23 and 5 per prevalence) 
teenagers and young by working -CDC data for homosexual I 00,000, respectively. 
-Prevalence in young 
adults in 1988 and backward 1987-defined activity when black & Hispanic men 
1993. from AIDS AIDS reporting (esp. Incidence of HIV was higher stable b/c increased 
surveillanc opportunistic during early for young minority men than in incidence in teenagers and 
e data on illnesses are epidemic) young white men for all modes heterosexuals offset 
the basis of estimates and may of transmission. reductions in homosexual 
the natural be imprecise men and injection drug 
history. -Natural history Incidence of HIV was higher users in their 20's 
could vary across in young minority women than -Increasing HIV 
. risk groups~ faster white women for injection prevalence among women 
progression than drug use and heterosexual aged 20-25 from increased 
estimated could contact. heterosexual transmission 
result in HIV 
-From 1983 to 1993, 
incidence being too The overall number ofHIV blacks comprised an 
high cases decreased by 45% in increasingly significant 
white men, increased slightly proportion of all estimated 
in black men, and decreased HIV cases (my own 
slightly in Hispanic men from conclusion) 
1988-1993 among those age 
23-27. 
~ ''''""nflll!'''~'~'~tH•I,WT'!'''' 
Table 8. Evidence Table for Dean, Steele, Satcher, & Nakashima, 2005 
Author, Year, Study Potential for Potential for Potential Important Results Conclusions 
Study Question Design Selection Measurement for Con-
Bias Bias founding 
Dean, H.D., Steele, Analysis of Moderate Minimal Moderate -From 2000-2003 in the 32 Overall Quality: Fair 
C.B., Satcher, A.J., National states. 45% of male HIVIAIDS 
and Nakashima, Survei- -HIVData: -Recent diagnoses -Those of cases & 69% of female cases -Minority races are 
A.K., 2005. llance Data Only from 32 aren't necessarily lower SES were black disproportionately affected 
states using new cases maybe -HIV I AIDS diagnosis rate was byHIV 
To examine the HIV name-based screened or 741100,000 for blacks and -Race & ethnicity are not 
epidemic among reporting of HIV tested at higher 91100,000 for whites risk factors for HIV, but 
minority races and infection since at or lower rates -AIDS diagnoses rates in 2003 markers for 
ethnicities in the US least 1999 than those of were approximately 8 and 13 socioeconomic factors 
-32 states higher SES times higher for black males -Given the high HIV 
account for 57% -Those of and females than white males prevalence in the black 
of US population lower SES and females, respectively. community, even "low-
and 44% of all maybe more -Blacks accounted for 53% of risk behavior" can pose a 
AIDS diagnoses likely to be estimated deaths among those higher threat of HIV than 
in the US reported with AIDS in communities with a 
-Omits NY, II, & lower prevalence 
Ca 
-This analysis may be used 
-Cases must be to direct prevention 
reported to be activities, such as the 
measured (many Minority HIV I AIDS 
not tested or Research Initiative 
tested (MARl), Sisters Informing 
anonymously- Sisters about Topics on 
which aren't AIDS (SISTA), and 
reported) Advancing HIV 
Prevention (AHP) 
initiative I 
Table 9. Evidence Table for: 
CDC. Trends in HIV I AIDS Diagnoses -- 33 States, 2001-2004. 2005. 
Author, Year, Study Potential for Potential for Potential Important Results Conclusions 
Study Question Design Selection Measurement for Con-
Bias Bias foundin11: 
Center for Disease Analysis of Moderate Minimal Moderate Blacks accounted for 51% of Overall Quality: Fair 
Control & National persons with HIV I AIDS 
Prevention, 2005. Surveillanc Only used data -Recent diagnoses -New addition diagnosed ( 68% among Decreased rates among 
eData from 33 states aren't necessarily ofNY data is females and 44% among black could be from 
Trends in HIV I AIDS using name- new cases large enough males) differential change in 
Diawoses- 33 based reporting to change -29% were white, 18% were testing patterns among 
States, 2001-2004. (estimated to estimates of Hispanic various populations, 
represent only incidence/prev -Non-statistically significant decreased incidence of 
To measure trends in 63% of all AIDS alencewhen decrease in HIV I AIDS HIV infections, or the 
HIV I AIDS Diagnoses cases in US compared to diagnoses from 2001 to 2004. effect of additional data 
from 2001-2004. during 2001- previous -5.0% average annual decrease added to the national 
2004) reports from in rates among blacks surveillance system 
CDC 
California is not -Recent 
included changes in 
reporting 
requirements 
Table 10. Evidence Table for: Ross, Grant, Counsell, et al., 1999 
Author, Year, Study Potential for Potential for Assessment & Important Results Conclusions 
Study Question Design Selection or M easu rem en t Weighting of 
Publication Bias Methodological 
Bias Quality 
Ross, S., Grant, A., -System a tic Mode rate Significant Poor -Potential barriers to Internal Validity: Poor 
Counsell, C., et al., Review of potential for bias patients were patient External Validity: Poor 
1999. studies from -Searched -Reported concerns such as 
1986 to 1996. Medline, -No discussion of inclusion/ex cl us ion additional demands on -To overcome barriers with 
To systematically Em base, and inter-rater criteria for abstracts patient, patient clinician recruitment, 
review barriers to -Identified CINAHL agreement -Two reviewers preferences for a RCTs should address an 
clinician and 9732 -Do not discuss extracted data from particular treatment, important question, have a 
patient participation references search strategy articles worry about uncertainty clear and simple protocol, 
in randomized -265 of these -Do not discuss independently. of treatment or trials, and require as little as possible 
trials. identified any attempts to -No discussion of patient concerns about from the clinicians, and 
clinician or acquire assessing internal information and consent. have straight-forward data 
To make patient unpublished validity -Physician concerns collection. They should 
recommendations participation data -Methods for hindering patient also include dedicated 
for improving the as an -Majority of systematically participation were research staff to support 
conduct of trials important papers are from reviewing qualitative protocol causing clinical staff and favor 
based on the issue Cancer research, studies are still in problems with pragmatic trial designs. 
findings. -78 of these the U.S., and are development recruitment, clinician -To overcome barriers with 
reported hospital based concerns about patient participation, 
original in formation provision to demands of the study 
empirical patients, and clinician should be as minimal as 
evidence influencing patient possible, clear explanation 
decision not to join. of the extent and purpose 
of the study should be 
provided, and support for 
the decision to participate 
sh auld be provided. 
Dedicated research staff 
should be used for 
providing information, 
obtaining patient consent, 
and monitoring the 
recruitment process. 
Table 11. Evidence Table for: Freimuth, Quinn, Thomas, et al., 2001 
Author, Year, Study Potential Potential for Potential for Important Results Conclusions 
Study Question Design for Measurement Confounding 
Selection Bias 
Bias 
Freimuth, V.S., Qualitative Minimal Moderate Moderate MAccurate knowledge Internal Validity: Fair 
Quinn, S.C., Methods about research was External Validity: Limited due 
Thomas, S.B., et using seven -Targeted -Don't discuss -Previous limited to small sample size and 
a!., 2001. focus groups diverse whether knowledge of the -Lack of understanding unconfirmed saturation. 
of African populations saturation was Tuskegee study and trust of informed Geographic diversity is a 
To examine Americans in for reached~ may -Past participation consent procedures was strength, however. 
knowledge of and four regions recruitment. have missed in research problem a tic 
attitudes toward of the U.S. -One important themes -Limited -Distrust of researchers -Measures to increase 
medical research, moderate- demographic data posed a substantial barrier participants' understanding of 
knowledge of the income for 8 of the 60 to recruitment informed consent and research 
Tuskegee Syphilis focus group participants -Participants felt research procedures are necessary. This 
Study, and in Chicago was important, but clearly should involve methods to 
reactions to the did not distinguished between the improve individual studies' 
HOME Box Office occur-may types of research they communication to participants as 
production, Miss weaken would be willing to well as a mass communication 
Evers' Boys, a external participate in and their campaign about research. 
fictionalized validity motivations for doing so. -Increasing trust between African 
version of the 
-Many did not distinguish Americans and researchers is also 
Tuskegee Study. well between treatment, paramount. Researchers shOuld 
prevention, and research. address concerns about scientific 
-Privacy, Masking, and misconduct proactively, factually, 
trust were important in and clearly. 
affecting willingness to -Merely including minority 
participate researchers and staff is not 
sufficient to increase minority 
recruitment. Professional 
programs in the Schools of 
medicine and public health should 
include preparation about culture, 
race and class, and working with 
diverse populations. 
Table 12. Evidence Table for Shavers. Lynch. & Burmeister. 2002 
. 
Author, Study Potential Potential Potentia Important Results Con elusions 
Year, Design for for I for 
Study Selection Measure Confou 
Question Bias ment Bias nding 
Shavers, V .L., Cross- Mode rate Minimal Moderate -Education associated with willingness to participate in Internal Validity: Fair 
Lynch, C.F., sectional a medical research. study (p=O.OS). External Validity: Inner 
Burmeister, survey of -Differential -Two -Survey -Among respondents who believed that minorities bore city & suburban 
S.F., 2002. the Detroit non- different technique the greatest burden of medical research risks, 55% of communities in Detroit-
Primary coverage survey used per blacks compared to 88% of whites indicated that they'd may not generalize to 
~A !so see Metropolit bias from techniques-- participant be willing to participate in medical research (p=:0.05). other geographic regions 
their 200 I an old census Mail vs. -Sex, -66% of blacks vs. 42% of whites reported that the 
publication. Statistical (greater in telephone education, poor bear most of the risks of medical research Different responses 
Area suburbs than (differential income, (p~0.04) between races about 
To examine during city) bias) age -81% and 28% of blacks and whites, respectively, were medical research risk 
racial 1998- -36% -Is survey aware of the Tuskegee study (p?O.Ol). sharing suggest a failure to 
difference sin 1999. Response validated or -49% of blacks vs. 17% of whites that reported that reconcile the belief that the 
the rate pilot tested? their knowledge of Tuskegee would affect their future poor bear a 
prevalence of participation indicated an unwillingness to participate disproportionate burden of 
sociocultural (p~0.05). risks with the fact that 
barriers as a -In multivariate analysis of blacks, only knowledge of racial minorities are 
possible Tuskegee Study and changes in trust of medical disproportionately 
explanations researchers due to this knowledge were significantly represented among the 
for the under~ associated with future willingness to participate in poor. 
representation medical research. After adjusting for changes in trust, -Having knowledge alone 
of African blacks who knew about the Tuskegee Study were more of the Tuskegee study does 
Americans in likely than those who didn't to be willing to participate not seem to influence 
medical in a medical research study in the future (OR= 464.4, willingness to participate in 
research 95% CI 44.4-486.4). Willingness was lower if effect research. Tuskegee's role 
studies of knowledge was a reduction in the level of trust of appears to be its 
medical researchers (OR=0.21, 95% CI 0.07-0.98) contribution to overall 
when compared to no change in trust and increased distrust of medical 
level of trust. researchers among African 
-Multivariate analysis for whites showed edUcational Americans. 
level and beliefs about racial sharing of medical 
research risks predicted their willingness to participate 
in medical research studies. 
~··~···~ ~··· .. 
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Table 13. Evidence Table for: Corbie-Smith, Thomas, St. George, 2002 
Author, Year, Study Design Potential for Potential for Potential for Important Results Conclusions 
Study Selection Measurement Confounding 
Question Bias Bias 
Corbie-Smith, G., Cross-sectional Moderate Minimal Minimal -Age, Education, Internal Validity: Good 
Thomas, S.B., St. survey of 909 Employment, Iocome and External Validity: 
George, D.M.M., individuals of -Had to have -Constructed a -Assessed for Region were significantly Generalizes well to 
2002. black and white phone validated scale for effect associated with race. general U.S. population, 
race in the U.S. -Refusal rate distrust outcome modification -Race, sex, education, but sampling techniques 
To examine similar for two measure. -Controlled for employment, and region may have excluded the 
possible Sampling design sample groups -Sensitivity possible were significantly very poor or the very 
differences in appears to be (49.6%) analyses done w/ confounders: associated with distrust. busy. 
distrust by race case-control, but different education, -Education, Employment, 
and to determine analyses were categorical cutoffs employment, and and Region considered After adjusting for markers 
to what extent done according of outcome region confounders in of social class, African 
other to race- variable and w/ multivariate analysis Americans are still less 
sociodemographic ignoring the outcome as a -African Americans have trusting of medical 
factors explain original continuous a higher prevalence of researchers than Whites. 
any racial sampling design. variable. distrust than Whites SES only had a small effect 
differences in (p<O.Ol). on distrust (6%). 
distrust. Sample weighted -When adjusted for -Recruitment in African 
to be nationally covariates, African American community 
representative. Americans have more should be thought of as a 
odds of having distrust process of ongoing 
than Whites (OR~4.7, engagement, dialogue, and 
. 
95% CI 2.9-7. 7) . feedback. 
Table 14. Evidence Table for: Stone, Mauch, Steger, 1997 
Author, Year, Study Potential Potential for Potential for Important Results Conclusions 
Study Question Design for Measurement Confounding 
Selection Bias 
Bias 
Stone, V.E., Cross- Minimal Moderate Moderate -Sex, Race, Injection drug Internal Validity: Fair 
Mauch, M.Y., Sectional use, and disease severity External Validity: 
Steger, K., et al., survey of -Don't tell -Didn't test for -Race concordance stat. significantly Generalizable to urban minority 
1997. symptomatic how interaction for of interviewer associated with clinical patients who are poor, in care, 
HIV patients acquired one variable -Learning of trials trial participation. and symptomatic. 
To determine receiving convenience -Possible race elsewhere -Race and injection drug 
whether ongoing sample. concordance -Knowledge use remain significant ~Persons of color and injection 
participation rates ambulatory with interviewer Outcome: could be after adjustment for drug users were significantly less 
of women, persons care at a confounded by disease severity, age, likely to participate in clinical 
of color, and municipal race con~ cordance education, and clinic type. trials than others with HIV despite 
injection drug users teaching of clinic staff, ~Sex and race stat. the presence of on-site clinical 
in AIDS clinical hospital. education, associated with being kept trials. 
trials are similar to dementia, or informed of new HIV ~Persons of color were less than 
those of other disease severity treatments and half as likely to cite ineligibility 
HIV/AIDS experimental drugs and as their reason for not 
patients. being told of clinical trials participating, twice as likely to 
for which they are report lack of interest as their 
To examine eligible. reason for not participating, and 
whether differences ~For most commonly less likely to report being 
in patients' cited reasons of informed of clinical trials. Thus, 
knowledge of non participation, race was non~whites do not perceive their 
clinical trials or stat. significantly lack information as an important 
reasons for not associated with disinterest determinant in their decision to 
participating or not wanting to participate. 
explain differences participate and non~ -Efforts that go beyond placement 
in participation eligibility. of AIDS clinical trials units in 
rates by gender, underserved areas are necessary. 
race, or drug use. -There is a great need to educate 
all HIV/AIDS patients and their 
physicians about clinical trials and 
---- ----
___ t~~-~!: _rarticipation. 
-
Table 15. Evidence Table for: Mills, Wilson, Rachlis, et al., 2006 
Author, Year, Study Design Potential for Potential for Assessment & Important Results Conclusions 
Study Selection or Measurement Weighting of 
Question Publication Bias Methodological 
Bias Quality 
Mills, E., Wilson, -Systematic Minimal Moderate Good -Major barriers to Internal Validity: 
K., Rachlis, B., et Review of participation included Good 
a!., 2006 qualitative and -Sought -No discussion of -2 reviewers fear of side-effects, External Validity: 
quantitative unpublished inter-rater independently distrust of researchers, Medium to high 
To systematically studies. studies from agreement for reviewed abstracts & general concerns about income nations 
review the Clinica!Trials.gov appraisal of papers for eligibility, research design, 
literature on Searched and UK National internal validity data extraction, and interference in everyday -The informed consent 
barriers and AMED, Research Register appraisal of validity life or changes in process should be 
concerns among Campbell, -Report inter-rater -Used checklist to routine, and social used to address the 
HIV patients to CINAHL, agreement for assess internal validity discrimination. important issues 
participation in Cochrane selection of papers -Report -Quantitative studies raised in this review 
I-IIV clinical drug Library, inclusion/exclusion indicated that the most -Researchers should 
trials. Em base, ERIC, criteria prevalent barriers were: clearly communicate 
Medline, and suspicions about he intentions and involve 
UK National drug itself (53%, 95% local investigators and 
Health Serice CI 27-83%), patients the I-IIV community in 
Economic were not informed or the research process 
Evaluation believed they were not -Investigators should 
Database. eligible (38%, 25-50%), clearly articulate 
and travel or transport means by which 
obstacles (39%, 21- confidentiality is 
57%). protected and adopt 
culturally sensitive 
and non-traditional 
changes to facilitate 
participation by those j 
typically under-
r~_presented. 
Table 16. Evidence Table for: Tello, Soong, Hunter, et al., 1998 
Author, Year, Study Potential for Potential for Potential for Important Conclusions 
Study Design Selection Measurement Confounding Results 
Question Bias Bias 
Tello, J., Soong, Cross- Moderate Minimal Moderate -67% of sample Internal Validity: 
S., Hunter, B., et sectional willing to Fair 
al., 1998. -Sampling -No mention of -Reason for visit is a potential participate. External Validity: 
Convenience method may be pilot-testing confounder -Those previously Generalizable to large, 
To evaluate the Sample from systematic/non- survey -Adjusted for age, gender, tested for HIV -1 urban STD clinics 
willingness of an STD Clinic random -Recall bias race, previous STD treatment, were more willing serving predominantly 
heterosexual STD in Birmingham, -Only 4 refused previous gonorrhea history, to participate in an heterosexual, black 
clinic clients to AL to participate previous genital herpes HIV vaccine trial populations 
participate in ->50% had history, knowledge of friends than those never 
clinical trials of current STD or relatives with HIV -1 tested (p~0.04). -This sample is 
vaccines to symptoms infection, previous HIV -1 -More females representative of the 
prevent HIV -1 testing, number of sex were willing to overall STD clinic. 
infection. partners in lifetime, use of participate than -Results are similar to 
crack cocaine, and use of males (p~0.08). or greater than many 
intravenous drugs -Sex and previous previously published 
testing for HIV -1 willingness estimates 
best predicted -In this sample, those at 
willingness to highest risk ofHIV-1 
participate, p~0.03 acquisition (men & 
&p=0.05 those never tested) were 
respectively. less willing to 
participate than those 
with less risk (women 
and those previously 
tested). 
------- ------ ---·· ----- -------
Table 17. Evidence Table for: Corbie-Smith, Viscoli, Kernan, et al., 2003 
Author, Study Potential Potential Potential for Important Results Conclusions 
Year, Study Design for for Confounding 
Question Selection Measure 
Bias ment Bias 
Corbie~Smith, Cross~ Moderate Minimal Minimal -Age, history ofvolunteerism, nursing Internal Validity: Fair 
G., Viscoli, Sectional home residence, and referral from a External Validity: Post 
C.M., Kernan, analysis of -Did not -history of -only con trolled physician were the socio-demographic menopausal women w/ 
W .N ., et al., those screened measure those volunteeris for education features significantly associated with history of TIA or stroke 
2003. for from 1993- m has regarding SES- giving consent to participate in Connecticut 
participation in May 1996. possible income not -When stratified by race, employment 
~To examine the the Women's ~988 potential recall bias measured was significant for black women and ~There was no difference in 
influence of Estrogen for subjects not age, volunteerism, nursing home consent rates by race for 
race, other Stroke Trial screened b/c of residence and referral were significant the WEST cohort. 
socio- (WEST) after physician for white women as associated with -Younger age, h/o 
demographic June 1996. refusal consent to participate. hysterectomy, prior 
features, and estrogen therapy, 
clinical -Hysterectomy, prior estrogen volunteerism, and no 
ch arac te ristics replacement therapy, MMSE score, and cognitive impairment were 
on the Diabetes were the clinical features predictors of consent. 
willingness of significantly associated with giving -Including sufficient 
subjects to consent. minorities to represent their 
participate in a -When stratified by race, there were no burden of disease may not 
clinical trial. significant associations for blacks, yield participation rates 
while hysterectomy, estrogen therapy, high enough to definitively 
MMSE score, and diabetes were test differences by race. 
associated with consent to participate. Such exploratory analyses 
are still valuable, however, 
-In the total cohort, age, hysterectomy, for hypothesis generating 
MMSE > 24, volunteerism, and prior and planning possible 
estrogen therapy were independently future studies in minority 
ass()ciated with consent to participate. groups. 
-There were no significant associations 
for black worn en 
-Age, hysterectomy, MMSE > 24, and 
volunteerism were independently 
associated with consent for white 
women. . 
Table 18. Evidence Table for: Buchbinder, Metch, Holte, et al., 2004 
Author, Study Potential for Potential for Potential Important Results Conclusions 
I Year, Study Design Selection Bias Measurement for 
Question Bias Confound 
ing 
Buchbinder, Prospective Moderate Minimal Minimal -Stat. Significant association between Internal Validity: 
S.P., Metch, B., Cohort hypothetical willingness and actual Good 
Holte, S.E., et -Excluded data from -Were those -Adjusted willingness (p<O.OOI). External Validity: 
al.,2004 Invited those one site unable to contact Odds Ratios -Blacks more likely to refuse than Generalizable to 
previously -Of the 2531 (attempted actually ''passive for site, Whites ( adj OR=2.22, 95% CI 1.43- diverse racial and 
To examine the enrolled in contact), 30% were refusers?" demographi 3.45) risk groups with past 
relationship aniDV unable to contact, did -Risk behaviors c variables, ·Those with some college education participation in an 
between vaccine not fmish the screening and hypothetical risk group, are less likely to refuse participation IDV-related study 
hypothetical and preparedness in time to consider willingness to and than those with less than h.s. 
actual study (VPS) enrollment, or had participate were behavioral education (adj OR=0.44, 95% CI · -30% and -50% of 
willingness to to be incomplete screening taken from past variables 0.23-0.85) those who were 
enroll in an mv screened for data. responses (non- -Age and No. of sex partners defmitely and probably 
vaccine trial. eligibility ·Those unable to differential) associated w/ actual willingness ( willing to participate 
for a phase 2 contact were stat. unadj p<O.OO I) still refused to enroll. 
HIV vaccine significantly different ·Blacks cited concerns about trust, Past willingness was 
trial. from those contacted safety, trial logistics, and discomfort also significantly 
for race, age, and wl study staff more than Whites. associated with 
injection drug use, mv -Blacks cited concerns about having ineligibility for the 
exposure, and# of sex a positive antibody test often, but vaccine trial. Thus, 
partners at end ofVPS similar to other Whites. past willingness not a 
-Blacks cited concerns about perfect tool for 
reactions of others less than others. predicting future 
-94% cited altruistic reasons as enrollment. 
primary motivator for trial 
participation. 
'' '"lrnlr' '''I'"' ':111'1 ,,, .. 
Table 19. Evidence Table for: Colfax, Buchbinder, Vamshidar, et al., 2005. 
Author, Study Potential Potential Potential Important Results Conclusions 
Year, Study Design for for for 
Question Selection Measure Confoundi 
Bias ment Bias ng 
Colfax, G., Cluster Moderate Minimal Moderate -Nearly all participants agreed or Internal Validity: Fair 
Buchbinder, S., Double- strongly agreed to participating for External Validity: 
Vamshidar, G., Blind RCT -Don't -Possible -4% of men, altruistic reasons. Generalizable primarily to U.S. 
et al., 2005. discuss how over- but 55% of -3/4 joined to receive. current info on MSM at high risk of HIV 
61 sites, 57 many reporting of women were HIV acquisition. Results are less 
To describe in the U.S. excluded or altruistic black --1/2 joined to reduce their risk generalizable to women and 
participants' ineligible reasons or -Adjusted for behavior or to get protection from HIV persons of color. 
motivations for Details of . under- sociodemograp --1/2joined for free HIV testing 
joining the first randomizati Recruitment reporting of hie and sexual -Women were more likely than men to Most participants joined for 
phase 3 HIV on process methods other risk variables provide multiple reasons for joining altruistic reasons, but many also 
vaccine efficacy not given varied by reasons -Adjusted for -Women were stat. significantly more joined to gain protection and to 
trial, the site (non- study site likely than men to agree or strongly reduce their risk behavior. 
V AX004 trial, Study -Selection differential) -Don't know agree with joining to receive free HIV -Compared to non-HIV related 
and to identify population criteria how well testing, reduce risk behavior, for studies, altruism appears to play a 
the were MSM different for randomization financial reimbursement, to obtain more important role in the 
demographic and women men vs. worked current information on HIV, and to get decision to participate. 
and behavioral at risk for women protection from HIV -The most sexually active 
correlates of heterosexual (women -After adjustment, sex and having 13 or participants were strongly 
study transmission may have more sex partners in past 6 months motivated by protection and least 
participation. been more were associated with joining the trial motivated by risk behavior 
"high risk") for protection. reduction, despite having had pre-
-Very few 
-After adjustment, sex, unprotected trial education. 
women anal or vaginal sex in past 6 months, 13 -Women and persons of color 
enrolled or more sex partners in past 6 months, were more likely to report joining 
and educational level were associated for multiple reasons, including 
with joining trial to reduce risk. Race receiving services. Additional 
was nonsignificant (OR=2.0, 95%CI public health efforts may be 
1.0·4.4) needed to ensure adequate access 
-After adjustment, sex, race, 13 or more to these services outside of trials. 
sex partners, and education were 
associated with joining for composite 
personal benefits. 

FIGURE 1. Estimated AIDS incidence*, deaths, and prevalence, by quarter-year o,f 
diagnosis/death- United States, 1981-2.000 
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•· Adjusted for reporting delays. 
Figure 1. U.S. AIDS Incidence, Prevalence, and Mortality, 1981-2000 (CDC, 2001) 
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FIGURE 5. Number of prevalent AIDS cases among persons aged 213 years, adjusted 
for delays in reporting, by quarter year- United States, 19£3-June 1996* 
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*Points represent quarterly prevalence; the line represents "smoothed" prevalence. Estimates 
are not adjusted for incomplete reporting of diagnosed AIDS cases or AIDS deaths. 
Figure 2. Taken from: CDC, 1997. MMWR, 46(08);165-173. 
Figure 1: Estimated New AIDS Cases, Deaths Among Persons 
with AIDS & People Living with AliOS., 1985-2UI)42, 13 
00.000 450000 
! 00,000 l 1~. ~C.oo:ooo 
0 l ."\. ~ .... 300,000 1:; 10 000 ~ f ' 
a oo.ooo 300,000 ~ 
Ul ........ < g 50000 2•!YD,OOO fii < . 
~ 40,000 - 'J ·- 200,000 t1!l z ~:5 
':g 33,000 / 1&1 000 > 'II I - :J ~ 20,000 10D.OOD ..,... ::11 
-l-50,000 Q 10,000 
0 0 
1!lllli!> 1931; 151.'!1'1'l0!$1!!1le 1!Se<C•195>115192: 1~ 195>419!l<& 19'3;; 195>7" 19'.!1;19Se2DIJ:) :;!!D1 ~ :<m4 
I New AIDS Cases Deaths U'Wng I 
Figure 3. Taken from the HIV/AIDS Policy Fact Sheet. Kaiser Family Foundation, 2005. http://www.kff.org/hivaids/upload/3029-06.pdf 
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U.S. HIV Mortality, 1987-2003 
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Figure 5. Data for graph found in: 
National Center for Health Statistics. Health, United States, 2005: With Chartbook on Trends in the Health of Americans. 
Hyattsville, Maryland: 2005. http://www.cdc.gov/nchs/data/hus/hus05.pdf 
U.S. Years of Potential Life Lost Before Age 75 
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Figure 6. Data for graph found in: 
National Center for Health Statistics. Health, United States, 2005: With Chartbook on Trends in the Health of Americans 
Hyattsville, Maryland: 2005. http://www.cdc.gov/nchs/data/hus/hus05.pdf 
Figure 7. Figure taken from: 
CDC, 2006. HIV/AIDS Surveillance- General Epidemiology (through 2004). 
http://www.cdc.gov/hiv/topics/surveillance/resources/slides/general/index.htm 
Figure 8. Figure taken from: 
CDC, 2006. IDV/AIDS Surveillance- General Epidemiology (through 2004). 
http://www.cdc.gov/hiv/topics/surveillance/resources/slides/general/index.htm 
Figure 2.1. HIV disease reports over time 
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Figure 9. Graph 
taken from:State of N.C., N.C. Dept. of Health & Human Services, Division of Public Health, 2005. North Carolina EpidemiologicProfile for IDV/STD 
Prevention & Care Planning. www.dhhs.state.nc.us 
Figure 2.2. Persons living with HIV in North Carolina, 2000-2004 
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Figure 10. Graph taken from: 
State of N.C., N.C. Dept. of Health & Human Services, Division of Public Health, 2005. North Carolina Epidemiologic Profile for HIV/Sl'D Prevention 
& Care Planning. www.dhhs.state.nc.ns 






U.S. Years of Potential Life Lost from HIV, by Race 
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Figure 17. U.S. Years of Potential Life Lost from ffiV, by Race 
Data for graph found in: 
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National Center for Health Statistics. Health, United States, 2005: With Chartbook on Trends in the Health of Americans 
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